Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683) Chemical Structure

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 103 Publications

20 Customer Reviews

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets
HDAC [1]
(Cell-free assay)
~10 nM
In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 M4CwcWtqdmG|ZTDBd5NigQ>? MVexJIg> NWXUU|dmTE2VTx?= MVLhcpRqNUiGQVOxJIFkfGm4aYT5JJdqfGhiSVO1NEBw\iByLkGxNkDPxE1? M{nkelEyQTZyNEi5
Friend leukemic cell M{T0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjLeow2OCEQvF2= M2PoS|czKGh? MVTEUXNQ NFfuNGVKSzVyPUCuPVkh|ryP M4Czd|EzOTB7OUGz
K562 NYDBbGpxU2mwYYPlJGF{e2G7 NUHmdnJoPiCq M3XJbWROW09? MkDyTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN MV:xNlQyQTN6MB?=
HT1080 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnZWZM4OiCq MnjPSG1UVw>? MV7JR|UxRTJwNDFOwG0> NID6UGkyOjJ5MEG3OS=>
H1299 NW\rb2NXU2mwYYPlJGF{e2G7 NEnVOXEzOCCvaX6= MojpSG1UVw>? Mn3JTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2= M1THclE1PTJzNEKy
H1299 M2XtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7QO|IhcA>? NEjHNJpFVVOR MmDrTWM2OD15LkK0JO69VQ>? MVWxOFUzOTR{Mh?=
HeLa MV;LbY5ie2ViQYPzZZk> MXSzNEBucW5? NXzW[YRnUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1? MmfBNVU3ODN7NEm=
LOX-IMVI NF3xZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzOFghcA>? NEj3S21KSzVyPUGuN{DPxE1? NXPNemxFOTV5MUW0O|A>
NCI-H226 NI\icnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX20PEBp NEO1S4JKSzVyPUKuOkDPxE1? MUmxOVcyPTR5MB?=
RXF-631L M2DsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7FbYoxPDhiaB?= Mnq0TWM2OD1{IN88US=> M{PUT|E2PzF3NEew
SNB-78 M4PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jtZ|Q5KGh? M3OxSWlEPTB;MU[g{txO NUPST5RYOTV5MUW0O|A>
St-4 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi0PEBp MoPuTWM2OD13LkKg{txO MkfuNVU4OTV2N{C=
ARP1 M3;KZmZ2dmO2aX;uJGF{e2G7 MofjNkDPxE1? NF7WWm43KGh? NYjWWGhFUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v NXLueWE3OTR5M{S4NFY>
CEM MoHUT4lv[XOnIFHzd4F6 MmTpNUBp MVXEUXNQ Mn:xTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? NGPQPZoyPjR{MEC2OC=>
HCT15 NXe4TWZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi0PEBp MXvHTVUxRTBwOEKg{txO MmXkNVY4OjN{Mke=
NCI-H23 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKxOFghcA>? NV;MPYM3T0l3ME2wMlkzKM7:TR?= MXmxOlczOzJ{Nx?=
GM15850 Mk\OT4lv[XOnIFHzd4F6 M1rHWVIvPSEQvF2= MYW5OkBp MkLCSG1UVw>? NHvIPIdKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW= Mn3xNVY6OjF|Nke=
GM15850 M{HxUWtqdmG|ZTDBd5NigQ>? MUmyMlUh|ryP M2fsdFk3KGh? NVyxO2ZpTE2VTx?= M2PsXmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC1JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n M1\VOVE3QTJzM{[3
GM15850 NEK0d2ZMcW6jc3WgRZN{[Xl? NXnCNGlVOi53IN88US=> MoXIPVYhcA>? NWLKeHZvTE2VTx?= M3nufWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxNkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= M1X3OVE3QTJzM{[3
GM15850 NF;IUZpMcW6jc3WgRZN{[Xl? NIHKfVgzNjVizszN NUPHUGo6QTZiaB?= MmHiSG1UVw>? NYHzS21tUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NYn3enh7OTZ7MkGzOlc>
GM15850 MlnsT4lv[XOnIFHzd4F6 M1vwfFIvPSEQvF2= MnGyPVYhcA>? NILGUJRFVVOR M3f6UGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n Mo\nNVY6OjF|Nke=
GM15850 M1\0OmtqdmG|ZTDBd5NigQ>? Mmm3Nk42KM7:TR?= NU\i[FNwQTZiaB?= NEDyU2tFVVOR MV;Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMU[gZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? MoPoNVY6OjF|Nke=
U937 MkHUSpVv[3Srb36gRZN{[Xl? MV[1JO69VQ>? NX3RPGZQOjRiaB?= MW\EUXNQ M2DzfmNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V? M4\BO|E4ODB2N{G4
H661 NXnURVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLDb3M1QCCq MmOxTWM2OD1zIN88US=> NFrtSngyPzF3N{CwPS=>
U937 NHnwT25HfW6ldHnvckBCe3OjeR?= MkLEOUDPxE1? Mnm4NlQhcA>? NVnMbHVNTE2VTx?= M33ERWlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36= NVzF[FBbOTd2NEe3OVA>
U937 NYi4NYdsTnWwY4Tpc44hSXO|YYm= MVWxJO69VQ>? NILLWG4zPCCq MYXEUXNQ M4q4dWVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u MW[xO|Q1Pzd3MB?=
RAW264.7 MUXGeY5kfGmxbjDBd5NigQ>? MXuxNEDPxE1? NWHTelczOjSq Mnr3e4F1\XJ? MYfJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR|UxKG:oIECuO|Yh|ryP NF7FVXgyPzR5N{WxPC=>
RAW264.7 M{LnU2Z2dmO2aX;uJGF{e2G7 MUmxNEDPxE1? M13ER|I1cA>? M{mwfpdifGW{ NHfsVJFKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKE6RIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDFwOEig{txO MnGzNVc1Pzd3MUi=
SC9 NEPTWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPIV5VXPDhiaB?= MVvJR|UxRTBwNkC2JO69VQ>? Mlz6NVc2ODd{MUm=
ST14A M3HJR2Z2dmO2aX;uJGF{e2G7 MXe1JI5O NVv0c3o5PzJiaB?= MYnJcoNz\WG|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO|aX;u M4fnZlE4PTZ3OUmz
ST14A M1rBZmZ2dmO2aX;uJGF{e2G7 NInUUoE2KG6P MkTwO|IhcA>? MV3JcoNz\WG|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>? MWGxO|U3PTl7Mx?=
PANC1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX4[WFXOSEQvF2= MnjJTWM2OD1yLkS1JO69VQ>? Ml;5NVc2QDh5NES=
PANC1 MV7GeY5kfGmxbjDBd5NigQ>? MYCxJO69VQ>? M1nafVI1KGh? NWHtWm91UW6lcnXhd4UhcW5icEKxW2FHOS:FSWCxJIdmdmViZYjwdoV{e2mxbh?= NH;jflEyPzV6OEe0OC=>
PANC1 MYHGeY5kfGmxbjDBd5NigQ>? M{DzTFEh|ryP M2rnO|I1KGh? M{\ZW2lv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO|aX;u M4TyWVE4PTh6N{S0
PT45 NVvqUHptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD12IN88US=> NVm3c29SOTd3OEi3OFQ>
ACHN Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S5OFIyKGh? M4DxV2dKPTB;MD62OUDPxE1? M2fEbVE4PjZ{NkC2
PC3 M{PoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXMdZB6OjFiaB?= M13tcGdKPTB;MD63NUDPxE1? Mle2NVc3PjJ4ME[=
A431 MVfDfZRwfG:6aXOgRZN{[Xl? M4r6ZVczKGh? NWnYVHRFUUN3ME20MlIh|ryP Ml;BNVc3QTF5NkO=
Cal27 NITkcYxEgXSxdH;4bYMhSXO|YYm= MnfPO|IhcA>? MYjJR|UxRTNwMjFOwG0> NYXOc254OTd4OUG3OlM>
CCRF-CEM NUjOT|J1S3m2b4TvfIlkKEG|c3H5 NYTURXN6PzJiaB?= M3T6UmlEPTB;MD64JO69VQ>? M3nv[FE4PjlzN{[z
EOL1 NUjrdXU1S3m2b4TvfIlkKEG|c3H5 MniwO|IhcA>? MkDlTWM2OD1zIN88US=> M17WVlE4PjlzN{[z
Hec-1-A MnXsR5l1d3SxeHnjJGF{e2G7 Ml34O|IhcA>? NXvlR3JOUUN3ME2xJO69VQ>? NHLGfpEyPzZ7MUe2Ny=>
HeLa NYDZZ|BpU2mwYYPlJGF{e2G7 M3vnTVExKM7:TR?= NWDv[lJyOzBibXnu MVrEUXNQ M1faO2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzFid3n0bEBKSzVyIH;mJFAvODJizszN NVTSfWJjOTd4OUG3OlM>
RKOp21 M13ERmN6fG:2b4jpZ{BCe3OjeR?= NGrpb444OiCq NYTVbmtEUUN3ME2xMlc3KM7:TR?= MmDRNVc3QTF5NkO=
Saos2 M1nxXmN6fG:2b4jpZ{BCe3OjeR?= NILrdIo4OiCq M{P5cmlEPTB;Mj6zJO69VQ>? MmLJNVc3QTF5NkO=
SK-OV-3 NWPKV|lkS3m2b4TvfIlkKEG|c3H5 NXfUTpExPzJiaB?= MmflTWM2OD1{LkKg{txO NY\4RVJyOTd4OUG3OlM>
U87MG NF;iZ4VEgXSxdH;4bYMhSXO|YYm= MUC3NkBp MnfVTWM2OD1zMTFOwG0> NE\KNIsyPzZ7MUe2Ny=>
NUGC3 NXPFb3BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf6bnI2KM7:TR?= NInZb2gzPCCq MUXHTVUxRTJwN{mg{txO M3PKdFE4QTB2OESz
CCD1059SK MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nqe2lEPTB;NEOuOUDPxE1? MVKxPFI1PzV3NB?=
HepG2 NIHjeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;US49iUUN3ME2wMlAxODZizszN M1X4Z|E5OjR5NUW0
HT1080 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX2WHhbUUN3ME2wMlAxOjRizszN Mn7jNVgzPDd3NUS=
SKBR3 NYf1d4FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW5THJKSzVyPUCuPEDPxE1? NH\xZoIyQDJ2N{W1OC=>
SNB78 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHRXdVTUN3ME2xOkDPxE1? NHjBZlIyQDJ2N{W1OC=>
SQ20B NIjC[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfjeVJKSzVyPUOg{txO NXv0U2RZOTh{NEe1OVQ>
St4 NVn1cFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\FR|UxRTVwMjFOwG0> NH;uWYkyQDJ2N{W1OC=>
MCF7 NXTwdHlJTnWwY4Tpc44hSXO|YYm= NHvIfIkyOCEQvF2= MlixPEBp M{GzWGROW09? MUXJcoR2[3Srb36gc4YhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u NI\sZXYyQDJ4OUKyOi=>
HEK293 MkHpT4lv[XOnIFHzd4F6 M3XjRVEhcA>? MYLEUXNQ M4\xOWlvcGmkaYTpc44hd2ZiSFTBR|Ehf2m2aDDJR|UxKG:oIECuNFMh|ryP NWfhTVZ6OTh|MEi1OlM>
HEK293 M4Xib2tqdmG|ZTDBd5NigQ>? NUjsSnRbOSCq MmPjSG1UVw>? M{HoWWlvcGmkaYTpc44hd2ZiSFTBR|Mhf2m2aDDJR|UxKG:oIECuNFU4KM7:TR?= NUDUS29bOTh|MEi1OlM>
G401 NX;jb3B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXhRpI4OiCq M3SwfWROW09? MV3JR|UxRTFizszN NVfnTI1KOTh|N{CzO|M>
HeLa MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDLTVk4OiCq MUDEUXNQ NXyxfoVOUUN3ME2wMlQ3KM7:TR?= MkjCNVg{PzB|N{O=
Human renal epithelial cell M1zaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX63NkBp NX3FfpluTE2VTx?= MXXJR|UxRTF2IN88US=> MknnNVg{PzB|N{O=
U937 M1nWfGZ2dmO2aX;uJGF{e2G7 MlXxOUDPxE1? MlnoNlQhcA>? Ml3XTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>? M{ftdFE5OzhzMkO4
U937 NETWbJhHfW6ldHnvckBCe3OjeR?= MkTSOUDPxE1? NVrETFZKOjRiaB?= NHT2WJlKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u MonXNVg{QDF{M{i=
U937 NWTMcnB[TnWwY4Tpc44hSXO|YYm= NX3BdlJQPSEQvF2= M4XYS|I1KGh? NIHwPZhKdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44> MXqxPFM5OTJ|OB?=
U937 Ml\HSpVv[3Srb36gRZN{[Xl? NHXCSY82KM7:TR?= MViyOEBp M3rEXGlv\HWldHnvckBw\iCjcH;weI9{cXN? NYL6T|N4OTh|OEGyN|g>
U937 NXvRZXNnTnWwY4Tpc44hSXO|YYm= NUD2SVZ4PSEQvF2= NXrtfWEzOjRiaB?= NXHESm9zUW6mdXP0bY9vKG:oIHfyZY52dG:leYTpZ{BlcW[oZYLlcpRq[XSrb36= MnvZNVg{QDF{M{i=
U937 NEfzbZVMcW6jc3WgRZN{[Xl? M{O2SVUh|ryP M2jwTVI1KGh? NVflcI5HUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=> NEL3Z4MyQDN6MUKzPC=>
U937 MYnLbY5ie2ViQYPzZZk> MkTiOUDPxE1? NFLLWXQzPCCq MkLZTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNB?= MoH6NVg{QDF{M{i=
HEK-TE NFrOfpJHfW6ldHnvckBCe3OjeR?= NHzRTnM2KM7:TR?= Ml;MOog> MkfFSG1UVw>? M1\tPGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36= MYixPFQ{PDF2NB?=
HPDE6c7 MkLOR5l1d3SxeHnjJGF{e2G7 NX7MVI5LPTBizszN MWG3NkBp NVPTU|ZuTE2VTx?= NWWwfHpRUUN3ME2xMlMh|ryP NIfPWlcyQDR7NES2Ny=>
Human microvascular epithelial cell M3zucWN6fG:2b4jpZ{BCe3OjeR?= NG\EPIQ2OCEQvF2= MmXQO|IhcA>? NV3CRXlrTE2VTx?= Mn3yTWM2OD1zLkOg{txO NHrvO|IyQDR7NES2Ny=>
Hup T3 NXrvW5ZIS3m2b4TvfIlkKEG|c3H5 NHnUZ|I2OCEQvF2= NHPoWpA4Omh? MoDzSG1UVw>? NGrYVZVKSzVyPUCuPEDPxE1? NUfre5c1OTh2OUS0OlM>
Mia Paca2 NIDNVZBEgXSxdH;4bYMhSXO|YYm= MnO2OVAh|ryP M{\zbVczcA>? MVjEUXNQ MoPITWM2OD1zLkGg{txO NYrYRWY1OTh2OUS0OlM>
Panc 04.03 MVnDfZRwfG:6aXOgRZN{[Xl? MmXDOVAh|ryP MX:3Nog> MVfEUXNQ NEHmZpdKSzVyPUGuNkDPxE1? NY\2NXZtOTh2OUS0OlM>
SU 86.86 MXjDfZRwfG:6aXOgRZN{[Xl? NYnIcnhrPTBizszN MW[3Nog> MmHSSG1UVw>? MkniTWM2OD1zLkOg{txO NYLtUIhOOTh2OUS0OlM>
HEK293 M1rVRmtqdmG|ZTDBd5NigQ>? NXPWRXNbOyCq NESxSlBKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUN4IHX4dJJme3Orb36ge4l1cCCLQ{WwJI9nKDBwMEG5JO69VQ>? MoLZNVg2PTh4Nkm=
HeLa NYD1enBLU2mwYYPlJGF{e2G7 MX2yJIg> NVHnVYtNUW6qaXLpeIlwdiCxZjDueYNt\WG{IFjERWMhf2m2aDDJR|UxKG:oIECuNFg{KM7:TR?= MlT0NVg2PTh4Nkm=
RAW264.7 MoHwSpVv[3Srb36gRZN{[Xl? M2jMUVIh|ryP NX[1R|F2Oy53IHi= MX3EUXNQ NH6yO3dCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY5n\WO2ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO MmrpNVg3PDR7Nkm=
NB4 MXq0PIg> M4DMb2ROW09? NGDtfHFKSzVyPUCuOkDPxE1? NX60eZhjOTh5MkOzOFk>
HEK293 MV;GeY5kfGmxbjDBd5NigQ>? MoDMNVAh|ryP MmnHNlQhcA>? NEnIWGRFVVOR NH3MZ4lC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ> M130d|E6ODJ{Nke1
HCT116 NF3vN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3Nog> NHXPRnlFVVOR MULJR|UxRTBwM{Gg{txO MofjNVkxQDR{OUS=
HeLa M3T2XGtqdmG|ZTDBd5NigQ>? M3LqPFIh|ryP NWHIR|JjOzBibXnu MXXEUXNQ M1LPU2lvcGmkaYTpc44hd2ZiSFTBR|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= M1K4d|E6ODh2Mkm0
IGROV1 NHLDSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZO|IhcA>? M4\0bGROW09? M2HXcWlEPTB;Mj6yJO69VQ>? Mle1NVkxQDR{OUS=
IGROV1 NFnMXZNMcW6jc3WgRZN{[Xl? MWK1JO69VQ>? MYKyOEBp M4nHT2ROW09? MV7Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMheDV|IHHj[ZR6dGG2aX;u NUHxUoJzOTlyOESyPVQ>
IGROV1 MYLLbY5ie2ViQYPzZZk> NH;qXYQyOCEQvF2= NUDRRYtNPCCq NYm3d49VTE2VTx?= M3zhNmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mNUh2IHHj[ZR6dGG2aX;u M3LLe|E6ODh2Mkm0
IGROV1 Mkj0T4lv[XOnIFHzd4F6 MWGxNEDPxE1? M{n6eFQhcA>? MXPEUXNQ MU\Jcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44> M4LHVFE6ODh2Mkm0
T24 M4jzNmtqdmG|ZTDBd5NigQ>? M1T2PFMhcA>? M3O3XGlv\HWldHnvckBw\iCqaYP0c45mKEh|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>? NGPTeo4yQTB6NEO5OS=>
T24 M4DpZWtqdmG|ZTDBd5NigQ>? MkTlN{Bp Ml7rTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR|UxKG:oIECuNlUh|ryP NWPKVIhNOTlyOESzPVU>
HeLa NV7TXIN6U2mwYYPlJGF{e2G7 NGS0THEyPSCvaX6= MU\EUXNQ NFziR4dKdmirYnn0bY9vKG:oIFjERWM3KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAxNjB6NUWg{txO NIHod3EyQTB7M{i4OC=>
HeLa MYTLbY5ie2ViQYPzZZk> M4TxOlE2KG2rbh?= MmPqSG1UVw>? M1TuVGlvcGmkaYTpc44hd2ZiSFTBR|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN MVyxPVA6Ozh6NB?=
NCI-H69 NHntfoREgXSxdH;4bYMhSXO|YYm= M4flSVczKGh? MnTRSG1UVw>? MmX5TWM2OD1{LkC2JO69VQ>? NEjRU2UyQTB7M{i4OC=>
SKMES1 MVjDfZRwfG:6aXOgRZN{[Xl? NIXVXVE4OiCq M4K5T2ROW09? MkPETWM2OD1{LkSyJO69VQ>? NVnPb2ZYOTlyOUO4PFQ>
S2 NV;meoxvU2mwYYPlJGF{e2G7 NGnHZ2wxNjFvMUCg{txO NU\SWGdGOSCq NF7yO4ZKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>? M4LVRVE6OzF5NEWw
SHSY5Y MXfLbY5ie2ViQYPzZZk> M17sfFExKM7:TR?= MmTFOFghcA>? NXfsc45[TE2VTx?= NHj3PIdKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOUDPxE1? NH22ZWoyQTN2NEG3OS=>
SHSY5Y M2[xUmN6fG:2b4jpZ{BCe3OjeR?= M3n2RlExKM7:TR?= NGK3NXA1QCCq M3rJNGROW09? NXnCVJhVUUN3ME2yJO69VQ>? NID5W2IyQTN2NEG3OS=>
DMS114 NVXydWQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLBTng3PDhiaB?= MXjHTVUxRTJwOTFOwG0> NVrwZYdDOTl2MUmyNFU>
HBC5 M1Hhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHVd3k1QCCq MYnHTVUxRTF5IN88US=> MkHZNVk1OTl{MEW=
SNB78 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWzcG5CPDhiaB?= NHLzR3pIUTVyPUG2JO69VQ>? M4rwcFE6PDF7MkC1
HeLa M2rue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP3O|IhcA>? NHfBUYJFVVOR NFOySGdKSzVyPUCuOFYh|ryP MXKxPVQ1OTh2Nh?=
BHK M4H0fmtqdmG|ZTDBd5NigQ>? MWe1JO69VQ>? NWP5SIVXOjRiaB?= M3y4OGROW09? MkPnTY5pcWKrdHnvckBw\iCKRFHDO{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdIxie22jIH3lcYJz[W6nIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4> M4\PWFE6QTZ4N{i5
CFBE41o- NUS3eJJ[U2mwYYPlJGF{e2G7 MWm1JO69VQ>? NF\LRXg5KGh? Mo\6SG1UVw>? NXjiNldQUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=> MUWxPVk3Pjd6OR?=
CFBE41o- M{TXeGtqdmG|ZTDBd5NigQ>? NHnuV|I2KM7:TR?= NYGybWxIPCCq NYn6T3luTE2VTx?= MUfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5ibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gcIV3\Wx? MXyxPVk3Pjd6OR?=
CFBE41o- M2G3TWtqdmG|ZTDBd5NigQ>? NXnlSYhsOSEQvF2= M1SxZlEhcA>? M370W2ROW09? MXTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu M4m3WlE6QTZ4N{i5
Primary bronchial epithelial cell NWq5fZd[U2mwYYPlJGF{e2G7 NUTXT3gxOSEQvF2= NFv4cWYzPCCq MWHEUXNQ MlrFTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v M3HWdVE6QTZ4N{i5
CFBE41o- M3:wZWtqdmG|ZTDBd5NigQ>? MVGxJO69VQ>? NILsN2Y2KGSjeYO= MkThSG1UVw>? NUGxdmNrUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5? NYTqdlZsOTl7Nk[3PFk>
CFBE41o- NYfPbXp{U2mwYYPlJGF{e2G7 NIfPdVcyKM7:TR?= MoKwNlQhcA>? NH3S[pNFVVOR MX\Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hfHKjZn\pZ4tqdmd? M{DLflE6QTZ4N{i5
CFBE41o- MV3LbY5ie2ViQYPzZZk> M3fMelUh|ryP NIrISogzPCCq MY\EUXNQ MkDuTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1? MYqxPVk3Pjd6OR?=
CFBE41o- MV7LbY5ie2ViQYPzZZk> NWnKNoFlPSEQvF2= NX\LNWplOjRiaB?= NHvQPYJFVVOR NHjDZW5KdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu NELVUY0yQTl4Nke4PS=>
CFBE41o- MkHST4lv[XOnIFHzd4F6 M{fGN|Uh|ryP M13iZVI1KGh? Mm\2SG1UVw>? M2Tjc2lvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiY3;ydoVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJidILh[oZq[2urbnegeI8h[2WubDDzeZJn[WOnIHHzJIdtgWOxZn;ycS=> NXTVNVFsOTl7Nk[3PFk>
Primary bronchial epithelial cell M17zd2tqdmG|ZTDBd5NigQ>? MX21JO69VQ>? MV6yOEBp M4fnWmROW09? M4TlOGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v M3zPN|E6QTZ4N{i5
Primary bronchial epithelial cell MWLLbY5ie2ViQYPzZZk> NIfjV4cyKM7:TR?= NYfobYZZQTZiaB?= NIfzboNFVVOR NILUTJFKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN? M4TQXVE6QTZ4N{i5
BxPC3 NIf3bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD1Xmc4OiCq MUfJR|UxRTJwNzFOwG0> MoTXNlAyPDN5N{i=
CAL27 NWC0W4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlraO|IhcA>? MoLYTWM2OD1|LkeyJO69VQ>? NIT5d5AzODF2M{e3PC=>
Capan1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3PSHFLPzJiaB?= NXHCTo5uUUN3ME23MlMh|ryP M2nzV|IxOTR|N{e4
HCC827 NGLqZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX23NkBp NF3mdGNKSzVyPUGuPEDPxE1? MoPVNlAyPDN5N{i=
LNCAP M2jHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XyeFczKGh? M{fnfGlEPTB;MD61PEDPxE1? MmTZNlAyPDN5N{i=
NCI-H2122 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHCO|IhcA>? MnPyTWM2OD15LkWg{txO MoHUNlAyPDN5N{i=
NCI-H358 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rWcVczKGh? NIjSNGtKSzVyPUKuOUDPxE1? M2HEUFIxOTR|N{e4
SCC15 NHPVZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDTlczKGh? MUPJR|UxRTJwNEmg{txO M4K3bVIxOTR|N{e4
SCC25 NHe2d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3NkBp NXPEemoxUUN3ME2xMlk{KM7:TR?= MkTkNlAyPDN5N{i=
SKHEP1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\lWWU4OiCq NF;EVZNKSzVyPUOuOFYh|ryP NHX5b2EzODF2M{e3PC=>
BJ NUHJW|huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr2UY8yODBizszN MXK0PEBp M3HrR2ROW09? NHfkbXhIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=> NV\IU2tDOjBzNEO4OFA>
MUF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNFAh|ryP MVy0PEBp MnPvSG1UVw>? NVrReGx6T3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0> M3rFc|IxOTR|OESw
Caco-2 NIK2U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jpVlExOCEQvF2= MYG0PIg> MmXNSG1UVw>? MXTJR|UxRThwMTFOwG0> M1OxZlIxOTR|OESw
Caco-2 NGrJT3NMcW6jc3WgRZN{[Xl? NFfBdJk2KM7:TR?= MV[0JIg> M1rV[GROW09? NV;KOoQ1UW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm|dH;u[UBi[2W2eXzheIlwdiCLQ{WwJI9nKDBwMEO3JO69VQ>? M{H2NFIxOTR|OESw
Caco-2 M1L3UmtqdmG|ZTDBd5NigQ>? MUGwMlMyPiCwTTD0c{A{OS54IN88US=> MnTTOEBp M3PpTWROW09? NI[xb2xGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>? MXSyNFE1Ozh2MB?=
Caco-2 NFTac5JMcW6jc3WgRZN{[Xl? NHf3WmUxNjNzNjDuUUB1dyB|MT62JO69VQ>? M4\FN|QhcA>? MVfEUXNQ NIjKNZhGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>? NYnLc2R{OjBzNEO4OFA>
Caco-2 NV7uVI05U2mwYYPlJGF{e2G7 MYi2MlMzKG6PIITvJFY{OiEQvF2= MnzqOEBp NHXlZVlFVVOR MYjFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN MojmNlAyPDN6NEC=
Caco-2 M3vrbmtqdmG|ZTDBd5NigQ>? NGLMRYM3NjN{IH7NJJRwKDZ|MjFOwG0> MoDEOEBp MmTkSG1UVw>? MXvFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?= NH\MNVUzODF2M{i0NC=>
Caco-2 M3\tNGtqdmG|ZTDBd5NigQ>? MnnUNE4{OTZibl2geI8hOzFwNjFOwG0> NYPXepFMPCCq NUGwNYlnTE2VTx?= NICxUVhGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[= M{L5dlIxOTR|OESw
HepG2 M3u1bmtqdmG|ZTDBd5NigQ>? M{\EeVUh|ryP NUDPdWxPPmh? MYfEUXNQ NFTYWpRKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9v MVuyNFE1Ozh2MB?=
HepG2 NF[3UJBMcW6jc3WgRZN{[Xl? NX60dIV4PSEQvF2= M3W2PFZp M1\rOGROW09? NFe5TpZKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36= MUmyNFE1Ozh2MB?=
HepG2 NY\YbFhSU2mwYYPlJGF{e2G7 MWW1JO69VQ>? NUTzeYlPPmh? M{nBUmROW09? M3SzVmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36= MYWyNFE1Ozh2MB?=
HepG2 NXHnRoJ6U2mwYYPlJGF{e2G7 M3H1fFUh|ryP NGDC[GU3cA>? Mn3hSG1UVw>? M4Lhdmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36= NE[4PZMzODF2M{i0NC=>
COLO205 NGKyclRMcW6jc3WgRZN{[Xl? NYmzeXZ[OTBizszN M3HG[FI1KGh? Ml;zSG1UVw>? NVGwcHB{UW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEmFNUCgc4YhOi5{IN88US=> NY\pZZV{OjB2NUGzO|g>
SCC4 NVnCOoV1U2mwYYPlJGF{e2G7 NICzPXAyKM7:TR?= Mmf0NlRp NFPB[JFKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJVjfWyrbjDhZ4V1gWyjdHnvci=> M1XH[FIxPDV{MkK1
SCC4 MkfsT4lv[XOnIFHzd4F6 NXjZc|BiOSEQvF2= MVKyOIg> NF6wTYVKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=> Ml3DNlA1PTJ{MkW=
SCC4 MoTOSpVv[3Srb36gRZN{[Xl? M2nBflEh|ryP M4fiOlUhdWmw MXLB[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w MW[yNFQ2OjJ{NR?=
NB4 NUP4UGIyTnWwY4Tpc44hSXO|YYm= NF3yTIg2KM7:TR?= NHTjfXgzPCCq M3vlfWROW09? MVLD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn Mle5NlA1QTF2NEC=
NB4 MkLnT4lv[XOnIFHzd4F6 NWn0dXlsPSEQvF2= MlLYNlQhcA>? MYDEUXNQ NVrUc4VMUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu NXn0R4pvOjB2OUG0OFA>
NB4 M3vTc2Z2dmO2aX;uJGF{e2G7 MkHJOUDPxE1? MnLLNlQhcA>? M3zMNmROW09? M1nDR2lv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW|c3nvci=> NVzsVppGOjB2OUG0OFA>
NB4 NYHaT3ZMU2mwYYPlJGF{e2G7 MojYOUDPxE1? NXXKXGtFOjRiaB?= M3KwRWROW09? M1XwcmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v MVGyNFQ6OTR2MB?=
NUGC3 NIfzeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4XJhxT0l3ME2yMlk1KM7:TR?= MnjzNlA5PTB7N{G=
A549 MWHGeY5kfGmxbjDBd5NigQ>? NGmz[3o2KM7:TR?= MnXaN{Bp M2i0XGROW09? MmOyTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ M3PwTlIxQDV3MkC4
HUT78 M{\WfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;o[lczKGh? NGDqVZhFVVOR NF;BXXlIUTVyPUCuN{DPxE1? M1TVUVIxQDh2MkC4
U937 NEjpWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnkNJo4OiCq M2nMXGROW09? NXj3N5gzT0l3ME2wMlM6KM7:TR?= NHv0O48zODh6NEKwPC=>
A431 MnzqR5l1d3SxeHnjJGF{e2G7 NH;lR4s4OiCq NFvTc3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGVITlJid3n0bEBKSzVyIH;mJFQvOiEQvF2= M3rrVVIyODhyNkK5
A549 MWnDfZRwfG:6aXOgRZN{[Xl? M3rVb|czKGh? NHjpT41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvQCEQvF2= MkjsNlExQDB4Mkm=
CAL27 MYPDfZRwfG:6aXOgRZN{[Xl? MkW0O|IhcA>? MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjCzMlIh|ryP NUDwdIs1OjFyOEC2Nlk>
HeLa MnrzR5l1d3SxeHnjJGF{e2G7 NIP5T2Q4OiCq NIT6WJREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2= M1zlNFIyODhyNkK5
Sf21 NGjOb4ZMcW6jc3WgRZN{[Xl? NELUT5A{KGh? MnmxTY5pcWKrdHnvckBw\iCIbHHnJJRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOiEQvF2= NYftfZNSOjFyOEC2Nlk>
SKBR3 MlzYR5l1d3SxeHnjJGF{e2G7 MmHJO|IhcA>? MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlYh|ryP NGXEUmEzOTB6ME[yPS=>
SKOV3 NY\vSZBsS3m2b4TvfIlkKEG|c3H5 M2mwVVczKGh? MoDsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?= M{fUXFIyODhyNkK5
COR-L23 NGq0d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nnd|ExKM7:TR?= NUf4R5hxPzJiaB?= MnzvSG1UVw>? M{HF[mdKPTB;MT6xJO69VQ>? NUX5dHg5OjFyOEC2OFc>
DU145 NVHEW3EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\kNVAh|ryP MnvuO|IhcA>? NI[2T2lFVVOR Mly5S2k2OD1zLkC1JO69VQ>? M{HuN|IyODhyNkS3
LoVo M1HYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNEDPxE1? NFPMUHU4OiCq NFvue3VFVVOR MUfHTVUxRTFwNzFOwG0> MnLlNlExQDB4NEe=
MCR5-SV2 NYX3cIdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHtXIlKOTBizszN NXS1NotUPzJiaB?= NH;IOlJFVVOR NVvtZpVFT0l3ME2yMlEh|ryP NVPH[XUxOjFyOEC2OFc>
HCT116 M3HTVGtqdmG|ZTDBd5NigQ>? M{C3VFMxKM7:TR?= MoS5N|AhcA>? MmfjSG1UVw>? M{\WOWlvcGmkaYTpc44hd2ZiSFTBR|Yh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36= MVeyNVA5ODZ2Nx?=
HCT116 M4Phc2tqdmG|ZTDBd5NigQ>? M4nzb|MxKM7:TR?= MmHZN|AhcA>? NHvlU5hFVVOR NGna[G9KdmirYnn0bY9vKG:oIFjERWMyKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36= MVSyNVA5ODZ2Nx?=
U937 NIrmW4ZMcW6jc3WgRZN{[Xl? NXW3bZBbPSEQvF2= M{W2[FI1KGh? NEn6THhFVVOR Ml3FTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl? NYnBR24xOjF{OUK0PVI>
U937 M3\NR2tqdmG|ZTDBd5NigQ>? MXK1JO69VQ>? NVHLPZdGOjRiaB?= NFHJSXFFVVOR MXPJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMOTh? MnrTNlEzQTJ2OUK=
U937 MWLLbY5ie2ViQYPzZZk> NHX6[2Q2KM7:TR?= NXS2cFdZOjRiaB?= MWDEUXNQ NYDhUHhqUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKHCjbj3hZ4V1gWyjdHXkJIhqe3SxbnWgTFQhdGW4ZXy= MUiyNVI6OjR7Mh?=
U937 MVjLbY5ie2ViQYPzZZk> M{TwN|Uh|ryP NUezdINnOTVibXnu NI[2VmVFVVOR MnzSTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw> MlHtNlEzQTJ2OUK=
A2780 NVXBWolkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6PVYhcA>? MoTmSG1UVw>? MYHJR|UxRTFwNkKg{txO M3LrTlIyPjN2NEOw
COLO205 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7sNFQ{QTZiaB?= MWnEUXNQ M1TlWGlEPTB;Mj6xNkDPxE1? NFu4dXEzOTZ|NESzNC=>
Hep3B NVn3Ro1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO0PEBp NUe5dGRmTE2VTx?= Mk\zS2k2OD1zLkKxJO69VQ>? NV7UTpBkOjF5MUKxOFY>
GM11272 M2D1[WZ2dmO2aX;uJGF{e2G7 NUHjc4tkOTByIH7N MlK3O|IhcA>? NUn3dVRHTE2VTx?= NGnpOG9T\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O MkjYNlE5PDB5MU[=
CFBE41o M1naUGtqdmG|ZTDBd5NigQ>? M1flelUh|ryP NGTxZ2FFVVOR M1zDRWRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>? M1fIUVIyQTh2OUW4
CFBE41o M{THUWZ2dmO2aX;uJGF{e2G7 NEfV[|kyKM7:TR?= NEPzWXczPCCq MXTEUXNQ NEPWWXlT\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC|dYLmZYNmKGG|IHfsfYNw\m:{bYO= M3HWWVIyQTh2OUW4
DU145 NX\mcYlxU2mwYYPlJGF{e2G7 MViyMlUh|ryP MYCyOEBp NXn0[oRrTE2VTx?= NWf3[JdyUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IIXwdoVofWyjdHnvckBw\iCyMkH3ZYYyKHC{b4TlbY4h\XiycnXzd4lwdg>? NUnTd2tmOjJ{NkCxOlY>
DU145 MV;LbY5ie2ViQYPzZZk> NV;aOIpSPSEQvF2= M4fR[lI1KGh? NUPP[lk4TE2VTx?= MWXJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcGm|dH;u[UBJPCCjY3X0fYxifGmxbh?= NWfQZVY{OjJ{NkCxOlY>
DU145 M3f3eGtqdmG|ZTDBd5NigQ>? MkTkOUDPxE1? M2nqdFI1KGh? MnO4SG1UVw>? Mm\NTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGirc4TvcoUhUDNiaInw[ZJi[2W2eXzheIlwdg>? MX2yNlI3ODF4Nh?=
786-0 NUHUSW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HL[VYvOiEQvF2= MVO3NkBp MYPEUXNQ MlfrS2k2OD1|LkKg{txO MXuyNlQ{PTZ4OR?=
A498 M1TwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3BOk4zKM7:TR?= MVe3NkBp M3n6c2ROW09? NGrhNGpIUTVyPUGuOkDPxE1? NFSzWJgzOjR|NU[2PS=>
A549/ATCC NETjbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe2MlIh|ryP Mn7pO|IhcA>? NV7ZeINwTE2VTx?= MojJS2k2OD1zLk[g{txO MX6yNlQ{PTZ4OR?=
ACHN NF\peYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPPYFFPi5{IN88US=> M3qwXFczKGh? MmTrSG1UVw>? NHH2epFIUTVyPUGuN{DPxE1? NYTVbW06OjJ2M{W2Olk>
BT549 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPzdIc3NjJizszN M4DNOVczKGh? MkXHSG1UVw>? NGS4N2VIUTVyPUGuN{DPxE1? NHPuXGIzOjR|NU[2PS=>
EKVX NH\iWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnScmlpPi5{IN88US=> NEe5Xoo4OiCq MWnEUXNQ MWTHTVUxRTFwMzFOwG0> MkDGNlI1OzV4Nkm=
HCT15 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYOk4zKM7:TR?= MVm3NkBp MlHDSG1UVw>? MlLyS2k2OD1{LkWg{txO NHv3clQzOjR|NU[2PS=>
HOP92 M1T5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjV[m9WPi5{IN88US=> NX7mRZlIPzJiaB?= M2H2[WROW09? M2m3TmdKPTB;NDFOwG0> M4qyWlIzPDN3Nk[5
IGROV1 NFz2OI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy2MlIh|ryP NG\OTVA4OiCq MUXEUXNQ Mli4S2k2OD1zLkOg{txO NU\xeHRiOjJ2M{W2Olk>
LOXIMVI MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vqe|YvOiEQvF2= MVK3NkBp NIr3SHdFVVOR MnzqS2k2OD1zIN88US=> Mn;uNlI1OzV4Nkm=
M14 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfFOk4zKM7:TR?= M2nn[FczKGh? MXzEUXNQ NFjRN3FIUTVyPUGuN{DPxE1? NV:4SFdlOjJ2M{W2Olk>
MALME-3M NFntToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrU[2k3NjJizszN NIfkSFc4OiCq MXvEUXNQ MXrHTVUxRTBwM{Kg{txO MWOyNlQ{PTZ4OR?=
MCF10A M3;kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe2MlIh|ryP Ml\uOFghcA>? M3r0[GROW09? M1P1WGdKPTB;OT62JO69VQ>? M2WwO|IzPDN3Nk[5
MDA-MB-435 M1y0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjo[XU3NjJizszN MYm3NkBp MnH6SG1UVw>? NEDKcXdIUTVyPUCuOUDPxE1? MVqyNlQ{PTZ4OR?=
MDA-MB-468 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP6Ok4zKM7:TR?= MWS3NkBp NFO4OXdFVVOR NHi0[GlIUTVyPUCuOlMh|ryP NXTaRpRoOjJ2M{W2Olk>
MOLT4 NWXVO5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK2MlIh|ryP NWTjSFBOPzJiaB?= NIfMUWhFVVOR MY\HTVUxRTBwNDFOwG0> NXfBcnNrOjJ2M{W2Olk>
NCI-ADR-RES NYfkcWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV22MlIh|ryP MVK3NkBp NHz1Z4RFVVOR NWLPTnRIT0l3ME2wMlE3KM7:TR?= NIXhNmIzOjR|NU[2PS=>
NCI-H23 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniOk4zKM7:TR?= NUCzN413PzJiaB?= MXzEUXNQ MV;HTVUxRTFizszN NGLXRXkzOjR|NU[2PS=>
NCI-H322M NWD0fIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvPVYvOiEQvF2= MX63NkBp Ml2ySG1UVw>? NUnVOVhMT0l3ME2wMlc6KM7:TR?= NVPzfHJbOjJ2M{W2Olk>
NCI-H460 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHWdII3NjJizszN NHf2TFk4OiCq MUjEUXNQ NISzUJlIUTVyPUCuO|kh|ryP MVWyNlQ{PTZ4OR?=
NCI-H522 NIK1V|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\JNXA3NjJizszN NVXDfmxJPzJiaB?= M1m5VmROW09? MVLHTVUxRTBwNTFOwG0> NWXPbGQ3OjJ2M{W2Olk>
OVCAR3 NVHNRWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILnVo43NjJizszN NV7VZVVKPzJiaB?= NVTQfYRiTE2VTx?= MkCxS2k2OD1zLkOg{txO MVeyNlQ{PTZ4OR?=
OVCAR4 NIDsZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMOk4zKM7:TR?= NHH4cWU4OiCq Ml7vSG1UVw>? NXLyS2lqT0l3ME20JO69VQ>? M1;nRVIzPDN3Nk[5
OVCAR5 M3;PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO2MlIh|ryP M4jSOFczKGh? MUHEUXNQ NGPkc49IUTVyPUCuO|kh|ryP MkK0NlI1OzV4Nkm=
OVCAR8 NHO3dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3hOk4zKM7:TR?= NXv0cWhsPzJiaB?= NF25Xm5FVVOR NYXVPXE6T0l3ME2wMlUh|ryP MXiyNlQ{PTZ4OR?=
RXF393 NHrlPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDwXnA3NjJizszN MWq3NkBp MXzEUXNQ M1\FbGdKPTB;MT6zJO69VQ>? MVKyNlQ{PTZ4OR?=
SF268 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0UlYvOiEQvF2= MVe3NkBp NXu5fIw3TE2VTx?= NVnSOolHT0l3ME2xMlYh|ryP Mnv6NlI1OzV4Nkm=
SF295 NWfUVZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrvOk4zKM7:TR?= MWS3NkBp NHLNfoNFVVOR NFLMXHhIUTVyPUGuOkDPxE1? NWDZXWR[OjJ2M{W2Olk>
SF539 M2PLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS2MlIh|ryP M{LGV|czKGh? M2rvTWROW09? M4nGfWdKPTB;MjFOwG0> MVWyNlQ{PTZ4OR?=
SK-MEL-2 NGHNS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O0fFYvOiEQvF2= M4SzRlczKGh? NV7jZ5U{TE2VTx?= MkjaS2k2OD1zLkOg{txO MYqyNlQ{PTZ4OR?=
SK-MEL-28 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnOk4zKM7:TR?= NFfuOYo4OiCq M1r1SmROW09? M37YOGdKPTB;MTFOwG0> NYTZNnplOjJ2M{W2Olk>
SK-MEL-5 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULxclgyPi5{IN88US=> NHu3[W04OiCq NWfqfVJOTE2VTx?= NUD5Sm5RT0l3ME2wMlY{KM7:TR?= NF7zfo8zOjR|NU[2PS=>
SKOV3 NEC5N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK2MlIh|ryP M4jJbVczKGh? NYnncVJNTE2VTx?= Mnn0S2k2OD1zIN88US=> NVXybZhFOjJ2M{W2Olk>
SN12C NEDZS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5cWY3Pi5{IN88US=> M4jSU|czKGh? MYnEUXNQ MojVS2k2OD1{IN88US=> NVj4cWk1OjJ2M{W2Olk>
SNB19 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonYOk4zKM7:TR?= MUm3NkBp NWC4RZNqTE2VTx?= NFvoR|lIUTVyPUCuOlMh|ryP NV3iNoVOOjJ2M{W2Olk>
SNB75 M1TI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGzOk4zKM7:TR?= NYfHSI53PzJiaB?= NVvxcWFITE2VTx?= Mk\JS2k2OD1yLke5JO69VQ>? NY\nW2k{OjJ2M{W2Olk>
SR NHPpZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LnN|YvOiEQvF2= MXW3NkBp NIHXUI1FVVOR Mnz2S2k2OD1yLkSg{txO MVOyNlQ{PTZ4OR?=
T47D M{PTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHQdpY3NjJizszN NYHjOZJTPzJiaB?= NFX1bmlFVVOR NInUcWhIUTVyPUCuOUDPxE1? MVeyNlQ{PTZ4OR?=
TK10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrnRWI{Pi5{IN88US=> NHnPVVQ4OiCq MUTEUXNQ NWO0cHhkT0l3ME2wMlY{KM7:TR?= NH3wOnQzOjR|NU[2PS=>
UACC257 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWzTGNqPi5{IN88US=> NWXMXItyPzJiaB?= NIDuZY1FVVOR NGfiSHVIUTVyPUCuOUDPxE1? M4Lw[|IzPDN3Nk[5
UACC62 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1niclYvOiEQvF2= NVXJfFRDPzJiaB?= MkjDSG1UVw>? M{P5ZmdKPTB;MD60JO69VQ>? M2\uOlIzPDN3Nk[5
UO31 M{nFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPNOk4zKM7:TR?= M1\OOlczKGh? MkfQSG1UVw>? MUnHTVUxRTBwNTFOwG0> M1;RSVIzPDN3Nk[5
Hep3B NFzKNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37nRVQ5KGh? MXrEUXNQ NWTDTFR2T0l3ME2wMlY6KM7:TR?= NV;6UIFDOjJ2M{m4OlM>
BE(2)-C NEfJ[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\QW2J1PzJiaB?= Mmi0SG1UVw>? NHPqTFBKSzdyPUKg{txO NFvxeHczOjl|MkOxOi=>
Bel7402 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzndJA4OiCq MnTLSG1UVw>? MXfHTVkxRTF5IN88US=> Mk\BNlMxPjF|N{[=
Bel7404 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm3NkBp MWTEUXNQ NFnHV2NIUTlyPUG4JO69VQ>? NX25Om9[OjNyNkGzO|Y>
BGC823 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj1NFhXPzJiaB?= M3XDU2ROW09? Mn;XS2k6OD15LkWg{txO Mo\KNlMxPjF|N{[=
MGC803 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp Mm\5SG1UVw>? M4Tm[WdKQTB;MUCuPEDPxE1? M{PUZlI{ODZzM{e2
SGC7901 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jOO|czKGh? NUXH[npkTE2VTx?= MoLtS2k6OD17LkSg{txO NW\4U2JROjNyNkGzO|Y>
SKHEP1 NGX3T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{noUlczKGh? NFjsfVRFVVOR NW\jfGlKT0l7ME2xO{DPxE1? NVnmdHpoOjNyNkGzO|Y>
SMMC7721 NFrsUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwcJZrPzJiaB?= NEjveYNFVVOR MmPZS2k6OD1{MDFOwG0> NXLmb|VMOjNyNkGzO|Y>
NUGC3 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:1OIlHOTBizszN NXe2WFRRT0l;Mj65OEDPxE1? MUmyN|E3OzN|Mh?=
A2780 CisR MlnKT4lv[XOnIFHzd4F6 M1zyOVE5KGh? NV3tUGRxUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?= MYGyN|I2OjZyMx?=
CAL27 sens MkTYT4lv[XOnIFHzd4F6 M1vCVVE5KGh? M4jyNWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zOkDPxE1? M3zwb|I{OjV{NkCz
CAL27 CisR M4TBU2tqdmG|ZTDBd5NigQ>? M2L5VFE5KGh? Mn;0TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>? M1fCXlI{OjV{NkCz
KYSE-510 CisR NF7qcpVMcW6jc3WgRZN{[Xl? NVTYdYt1OThiaB?= NIr3PWVKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOVkh|ryP Ml;hNlMzPTJ4MEO=
KYSE-510 sens M{HjPWtqdmG|ZTDBd5NigQ>? NHzLVHEyQCCq NVTzTFYyUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlch|ryP Mlq0NlMzPTJ4MEO=
MDA-MB-231 sens NXfJdIIyU2mwYYPlJGF{e2G7 NFnqRW4yQCCq MoPOTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>? M33nRlI{OjV{NkCz
MDA-MB-231 CisR MX;LbY5ie2ViQYPzZZk> NUnJbIpjOThiaB?= MmHFTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>? MWSyN|I2OjZyMx?=
ES2 M{jPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[0[2VLPDhiaB?= MnfLSG1UVw>? MlniTWM2OD1zMj63JO69VQ>? NV;rXmY5OjN2OUO0OFk>
MDA-MB-231 MVvLbY5ie2ViQYPzZZk> M3OxUVExKM7:TR?= NF;BZlU{OCCvaX6= M1PTWWROW09? M4HJfGlvcGmkaYTpc44hd2ZiSFTBR|Ji NI\FPIIzOzR7M{S0PS=>
MDA-MB-231 NFzYRnVMcW6jc3WgRZN{[Xl? NVnRdXplOSEQvF2= NVewclMyOjRiaB?= MWTEUXNQ MnntTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjY3X0fYxifGmxbjDs[ZZmdHNib3[geJVjfWyrbh?= MYOyN|Q6OzR2OR?=
HS68 MlT2R5l1d3SxeHnjJGF{e2G7 NGm4VmIyOCEQvF2= NXfNd2tFPzJiaB?= M2DMWWROW09? MWXJR|UxRTRwNjFOwG0> M4DuN|I{PTdyNUSy
MEF M{fCSGN6fG:2b4jpZ{BCe3OjeR?= M3v0TFExKM7:TR?= MlPRO|IhcA>? MWPEUXNQ NYfaRY9HUUN3ME20MlQh|ryP NEjS[VEzOzV5MEW0Ni=>
BGC823 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFe|BFVVOR MVzHTVUxRTNwMEmg{txO MWGyN|YxOTdyNh?=
High5 MlOxT4lv[XOnIFHzd4F6 NHHZW5QzPCCq MYPJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JJdqfGhiSVO1NEBw\iByLkC5JO69VQ>? MX6yN|YxOjV{Mx?=
High5 MoG3T4lv[XOnIFHzd4F6 M1T0ZlI1KGh? NH\L[4JKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlEzKM7:TR?= M4TaZ|I{PjB{NUKz
High5 MXfLbY5ie2ViQYPzZZk> M{fYN|I1KGh? MUfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>? MYmyN|YxOjV{Mx?=
A549 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfXSG1UVw>? M1qzV2lEPTB;MT6wO|kh|ryP NIDT[ZEzOzZ2NEKxNC=>
HCT116 M{\nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKzUFdWTE2VTx?= NUTMUHF4UUN3ME2wMlc2PyEQvF2= NFvp[XEzOzZ2NEKxNC=>
K562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5SG1UVw>? MYDJR|UxRTBwNkS1JO69VQ>? MUeyN|Y1PDJzMB?=
GBC-SD Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2TXg2KM7:TR?= MXq3NkBp NGjuTmxFVVOR M2HUbWlEPTB;MUSuPEDPxE1? NFHNdIozOzdyN{K2NC=>
HGC27 NWnDPZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHpNphoPSEQvF2= MV[3NkBp M2PYO2ROW09? NF7NWoxKSzVyPUWuOEDPxE1? Mn7ONlM4ODd{NkC=
HL60 M1\S[2tqdmG|ZTDBd5NigQ>? MkDTOUDPxE1? M1ux[VI1KGh? NYTLTopOTE2VTx?= M3PVd2lvcGmkaYTpc44hd2ZiSFTBRy=> NU\0RYd3OjN5MEeyOlA>
Vero MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULmXXpFPzJiaB?= MX7EUXNQ Mo\4TWM2OD1yLkmg{txO NX\JXGdbOjN5OE[0OVI>
NCI60 MkTwR5l1d3SxeHnjJGF{e2G7 NGHmbI01QCCq MkXWSG1UVw>? M3;PTmdKRTBwNUOg{txO M2C3WFI1ODF3M{K3
SW620 MnezR5l1d3SxeHnjJGF{e2G7 NWjPcGx{PDhiaB?= MlvSSG1UVw>? NX;xZ41RT0l;MD61OEDPxE1? NFLrPWwzPDBzNUOyOy=>
U251 NIDMR2tEgXSxdH;4bYMhSXO|YYm= NUD4PFRwPDhiaB?= MoH5SG1UVw>? NG\je4dIUT1zLkWzJO69VQ>? MYSyOFAyPTN{Nx?=
KM12 Mmq2R5l1d3SxeHnjJGF{e2G7 NVX4UmZMPDhiaB?= NXTsSFRNTE2VTx?= MmmxS2k:OS56ODFOwG0> MVyyOFAyPTN{Nx?=
Hs578T MVrDfZRwfG:6aXOgRZN{[Xl? MXu0PEBp MlL6SG1UVw>? MnThS2k:PC56MzFOwG0> M2TPRlI1ODF3M{K3
MDA-MB-231 NI\hcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzZPZk1QCCq NUOwPZBnUUN3ME2wMlE3KM7:TR?= NH7yfW4zPDB7NUCxOi=>
MCF7 NV7VbJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG0PEBp NIXnV4VIUT1yLkS1JO69VQ>? M1zrSlI1OTF7NUW1
MDA-MB-435 NGPXUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DsXlQ5KGh? NYi2XW1yT0l;MD64PEDPxE1? NIHSdoIzPDFzOUW1OS=>
AsPC1 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSzNEDPxE1? M12x[FQ5KGh? MnHHSG1UVw>? M37Y[mlEPTB;Mz62OkDPxE1? NFzNenAzPDF6NUO3PC=>
Jurkat E6.1 MYHLbY5ie2ViQYPzZZk> NXrUUop3OiCq M{KxU2ROW09? NITqZ|ZKdmirYnn0bY9vKG:oIFjERWM1KHerdHigTWM2OCCxZjCwMlA1KM7:TR?= NUnHcHo{OjR{NkG4OlI>
KG1 NELXXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TzcFQ5KGh? MWrJR|UxRTFwMUWg{txO NVLDWWNtOjR3MkWwNFM>
HEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTqcHQ1QCCq MknoSG1UVw>? M{\lTmlEPTB;MD60PUDPxE1? NIf5ZoIzPDZ7NEC1OS=>
HSC3 NVnsTGw4S3m2b4TvfIlkKEG|c3H5 MmPrNVIhcA>? MnfsSG1UVw>? M3zW[2lEPTB;MD63NUDPxE1? MoG2NlQ4PjZ3NkC=
HT-29 MmfQR5l1d3SxeHnjJGF{e2G7 MWixNkBp MYDEUXNQ NWfqSpNyUUN3ME2wMlczKM7:TR?= NV3UXYZXOjR5Nk[1OlA>
KB MU\DfZRwfG:6aXOgRZN{[Xl? MUCxNkBp M2PCVmROW09? NFzvW29KSzVyPUCuO|Uh|ryP M3vhb|I1PzZ4NU[w
H460 NWLhV5RNS3m2b4TvfIlkKEG|c3H5 NX\NT5dSOTJiaB?= M3jkWmROW09? M3;kcGlEPTB;MD64NkDPxE1? M1HqcVI1PzZ4NU[w
MONE1 NEDMUlREgXSxdH;4bYMhSXO|YYm= MnzFNVIhcA>? NUi3WJJxTE2VTx?= Mnf1TWM2OD1zLkG4JO69VQ>? NV\jR4hTOjR5Nk[1OlA>
MKN45 NUnjcWNES3m2b4TvfIlkKEG|c3H5 MYixNkBp MojBSG1UVw>? MkL6TWM2OD1zLkK1JO69VQ>? MWWyOFc3PjV4MB?=
TSGH Mn73R5l1d3SxeHnjJGF{e2G7 M3PZOFEzKGh? M1e5TmROW09? MXHJR|UxRTJwMEmg{txO NGW2cGczPDd4NkW2NC=>
HL60 M2rSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfkeG44OiCq MmXBSG1UVw>? NX3XcYZVT0l3ME2wMlk{KM7:TR?= NYi5XpVxOjR7MEC1NFA>
HEK293 NWTMT2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC3NkBp NXP6ZpBiTE2VTx?= NUO2SGtXT0l3ME2xN{DPxE1? Mof3NlQ6ODB3MEC=
Jurkat MmTNR5l1d3SxeHnjJGF{e2G7 NYe2eHNtOTByIN88US=> NXj3XpdEPzJiaB?= M1y0SmdKPTB;MD65JO69VQ>? MUOyOFkxODd2Mx?=
GM15850 NIjjdFFMcW6jc3WgRZN{[Xl? MlPjNk42KM7:TR?= MU[5OkBp MmntSG1UVw>? M33Cb4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UAyPCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> MXmxOlkzOTN4Nx?=
GM15850 MXfLbY5ie2ViQYPzZZk> MojuNk42KM7:TR?= NYXP[YVRQTZiaB?= NY\OR5ZLTE2VTx?= MoTk[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NIizNnIyPjl{MUO2Oy=>
GM15850 MoLrT4lv[XOnIFHzd4F6 Mon2Nk42KM7:TR?= MoHiPVYhcA>? NXjRd3ZxTE2VTx?= MXfkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NELRbWIyPjl{MUO2Oy=>
GM15850 NGnwU|lMcW6jc3WgRZN{[Xl? NUO1dmZqOi53IN88US=> Mnr3PVYhcA>? M2PufGROW09? MoLl[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NXftV4h7OTZ7MkGzOlc>
GM15850 NHv6eFZMcW6jc3WgRZN{[Xl? M4\2[VIvPSEQvF2= MnHuPVYhcA>? MoXkSG1UVw>? MlTU[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NFvJVZcyPjl{MUO2Oy=>
GM15850 MnrLT4lv[XOnIFHzd4F6 NVjWVXFMOi53IN88US=> M{eyO|k3KGh? Mn:zSG1UVw>? M2j1WIRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NI\PdZkyPjl{MUO2Oy=>
GM15850 MlfLSpVv[3Srb36gRZN{[Xl? NUnBWHFrPSEQvF2= NFfkOYEyOiCq Mk\4SG1UVw>? NWH5dGxLcGG|IH7vJIVn\mWldDDvckBHYE5ibWLORUBmgHC{ZYPzbY9v NH22cJEyPjl{MUO2Oy=>
U937 MV;LbY5ie2ViQYPzZZk> M2XIRlUh|ryP Mme2NlQhcA>? MVHEUXNQ MmfCbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w MUSxO|Q1Pzd3MB?=
U937 MmT2T4lv[XOnIFHzd4F6 MnW2NUDPxE1? MnHDNlQhcA>? NUPx[FBQTE2VTx?= NV21fGxxcGG|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u NFjzfo4yPzR2N{e1NC=>
PANC1 MUjGeY5kfGmxbjDBd5NigQ>? NVXLVpd3OSEQvF2= M3;nOVI1KGh? MYjkc4V{KG6xdDDpcoNz\WG|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?= MnvrNVc2QDh5NES=
PANC1 NYXo[4k1TnWwY4Tpc44hSXO|YYm= NVntTZRLOSEQvF2= NEDRbGQ1QCBiaB?= M2K4N4Rw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO|aX;u MWqxO|U5QDd2NB?=
Caco-2 M4HTW2Z2dmO2aX;uJGF{e2G7 M4nQ[lUh|ryP MXyyOEBp NH3BdplFVVOR M3TnOIRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>? MV6yNFE1Ozh2MB?=
SCC4 NEP6[Y1HfW6ldHnvckBCe3OjeR?= MnnFNUDPxE1? MXmxNEBucW5? Ml3MSG1UVw>? MnLZbIF{KG6xIHHnc45qe3RiYXP0bZZqfHliYYSgWmRTKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBEYVB{NDDn[Y5mKGW6cILld5Nqd25? MYWyNFQ2OjJ{NR?=
A549 M1PPfWZ2dmO2aX;uJGF{e2G7 MnL1OUDPxE1? M3G0[FMhcA>? M1npfmROW09? Mmjq[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> M4G1U|IxQDV3MkC4
HCT116 MWrLbY5ie2ViQYPzZZk> MnLPNE4{KM7:TR?= M{\USVMxKGh? M4LtTmROW09? NWjm[IRN\G:nczDuc5QhcW6qaXLpeEBJTEGFMTDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKM1u5JIFk\XS7bHH0bY9v Mn\UNlExQDB4NEe=
HepG2 MVLGeY5kfGmxbjDBd5NigQ>? MYGxNEDPxE1? MmHINlQhcA>? MX\EUXNQ M2TieoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO= NWnIOVduOjF3NEi1PFI>
GM11272 Mlu4SpVv[3Srb36gRZN{[Xl? MnnPNE4yKM7:TR?= NF3BeI84OiCq M3W2UGROW09? MkPv[I9meyCwb4SgdoVi[3SrdnH0[UBO\UOyMjDteZRidnRiZYjwdoV{e2mxbh?= M{XkfFIyQDRyN{G2
MDA-MB-231 NVL1c4lUU2mwYYPlJGF{e2G7 MmP5NVAh|ryP NUTqVWQxPSCvaX6= MX3EUXNQ NIDwS|Rld2W|IH7veEBqdmirYnn0JGhFSUN{YR?= MofxNlM1QTN2NEm=
MDA-MB-231 MlLRT4lv[XOnIFHzd4F6 NYjhPINnOSEQvF2= MWSyOEBp Mm\QSG1UVw>? M4fZTIRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4> NH;HTI0zOzR7M{S0PS=>
K562 M1\5WGtqdmG|ZTDBd5NigQ>? Mn3z[I9meyCwb4SgbY5pcWKrdDDISGFE M2fReVI{PTlzMUGx
Jurkat M4Ll[mN6fG:2b4jpZ{BCe3OjeR?= NE[0epMzOCEQvF2= MmDQO|IhcA>? M2j6SWROW09? NYHmdIN7dm9iY4n0c5RwgGmlaYT5JIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9v Ml:4NlQ{ODR|NEi=
HCT116 NFPkNZVCeG:ydH;zbZMhSXO|YYm= NYnuZ3JXOyEQvF2= NHnMdmwzPCCq NWDYcGFUTE2VTx?= NIC5e2dld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bxem:2ZXnuJIxmfmWu NXTsbXFTOjR5Nk[1OlA>
KASUMI-1 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YS5RYUUN3ME25PU4yPyCwTR?= Mn35V2FPT0WU
KARPAS-45 NH7kVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF5Mz64PUBvVQ>? M1LZXXNCVkeHUh?=
BHT-101 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvDR5ZKSzVyPUK0OE4yQCCwTR?= MXPTRW5ITVJ?
H9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK3TnR6UUN3ME2yOVUvODRibl2= NF7nfYlUSU6JRWK=
PA-1 NUD4S|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0eJRwUUN3ME2yPFYvOjZibl2= NHmzeXFUSU6JRWK=
NEC8 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6wfGlKSzVyPUK4PU4{QCCwTR?= NWHhclFyW0GQR1XS
MHH-PREB-1 NGK2U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXJ[YN{UUN3ME2yPVQvPTNibl2= MVTTRW5ITVJ?
NB7 M17GS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnFTWM2OD1|NEWuO|Qhdk1? NI\ld|dUSU6JRWK=
A3-KAW NWDIcHBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XFXWlEPTB;NECwMlU6KG6P M2D6enNCVkeHUh?=
NB69 NYHsWFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRzMT63NUBvVQ>? NG\RUIZUSU6JRWK=
EoL-1-cell NGjYeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnOXGZsUUN3ME20OVQzPSCwTR?= M{\LS3NCVkeHUh?=
CHP-212 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGwTWM2OD12NUeuOVMhdk1? NXnmXXFXW0GQR1XS
C2BBe1 M4HEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{eyb2lEPTB;NEeyMlE6KG6P NH60e4NUSU6JRWK=
697 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4TGlEPTB;NEezMlQyKG6P NGj5eldUSU6JRWK=
BCPAP MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVyMT60NkBvVQ>? M{n1NnNCVkeHUh?=
L-363 NVewSWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTVyMz6xJI5O NX;IN2VNW0GQR1XS
ES8 NI\jZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT1[XhvUUN3ME21NlMvPTNibl2= M3j1WnNCVkeHUh?=
BE-13 NF2ydJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTV{Nj65OkBvVQ>? MXPTRW5ITVJ?
CTB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLaTWM2OD13M{euPVIhdk1? NI\KdlZUSU6JRWK=
HD-MY-Z NYjjfoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xTWM2OD13M{iuNVMhdk1? NUjie2ZCW0GQR1XS
NKM-1 M33LSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ERWlEPTB;NUS0MlI4KG6P M1LGNHNCVkeHUh?=
NCI-H720 NXLaWVllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DvW2lEPTB;NU[wMlE5KG6P MWDTRW5ITVJ?
KY821 M4DzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzwbZdwUUN3ME21OlMvOjVibl2= NYTDV4VIW0GQR1XS
OVCAR-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\rTWM2OD13N{[uNVEhdk1? MUPTRW5ITVJ?
CTV-1 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTV6MT61OkBvVQ>? Mke1V2FPT0WU
P12-ICHIKAWA NH\MU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTV7Nj61NUBvVQ>? NFuwdWxUSU6JRWK=
DB Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HUbmlEPTB;NUm4MlU4KG6P NIPCR3JUSU6JRWK=
CHL-1 M2TBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzjVGZKSzVyPU[0Nk4xQCCwTR?= MlWwV2FPT0WU
A4-Fuk Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnmPG15UUN3ME22OFQvQTFibl2= NITCXmlUSU6JRWK=
MV-4-11 NWqyeXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZ3OT6xJI5O NX;qeGxtW0GQR1XS
RPMI-8226 M4PzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTZ5OD6xPEBvVQ>? NGH2OFNUSU6JRWK=
NB14 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZ7Nj65OUBvVQ>? M4m0T3NCVkeHUh?=
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq0SmVKSzVyPUewOk43QCCwTR?= NGLjSZZUSU6JRWK=
D-423MG M4DlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\RN4xoUUN3ME23NFYvQDlibl2= NHfTZlRUSU6JRWK=
D-283MED NE\odmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTmTWM2OD15MUSuNVQhdk1? NUnMd|M3W0GQR1XS
ES1 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rZbGlEPTB;N{K0MlQhdk1? MXPTRW5ITVJ?
GOTO NVLqTnh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTd{OT6xNkBvVQ>? NHG5eWdUSU6JRWK=
NCI-H209 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Py[GlEPTB;N{K5Mlkhdk1? MXvTRW5ITVJ?
MOLT-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjRlBKSzVyPUezPE46QCCwTR?= NVnLV4FKW0GQR1XS
ATN-1 NWfCTIJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTd2MD6yPEBvVQ>? MXjTRW5ITVJ?
DU-4475 NVfIWVlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\JZoduUUN3ME23OVEvQTFibl2= NHHI[XZUSU6JRWK=
NB10 NUD5R|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DJXWlEPTB;N{WxMlkzKG6P MVPTRW5ITVJ?
KG-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmZWlEPTB;N{e1MlQ2KG6P NXvYTmo6W0GQR1XS
MOLT-4 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6xTWM2OD15OEeuOFYhdk1? NEGw[FNUSU6JRWK=
TE-1 NViwN|hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD15OUGuNUBvVQ>? NXOwN|RoW0GQR1XS
SBC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PHXWlEPTB;N{mzMlg1KG6P NVS4OohIW0GQR1XS
HEL NXSyc2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThyNj6wPEBvVQ>? NYC3[oVMW0GQR1XS
SK-MEL-2 M4nNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu0TWM2OD16MEmuOFQhdk1? MojJV2FPT0WU
KU812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PoZmlEPTB;OEGzMlEhdk1? NH;LcGZUSU6JRWK=
RPMI-8866 M1;yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K0SGlEPTB;OEGzMlY4KG6P NIPobYRUSU6JRWK=
ALL-PO MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WxW2lEPTB;OEG0MlY3KG6P M{jhXnNCVkeHUh?=
LU-139 NInKWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;4ZnBKSzVyPUiyNk45PiCwTR?= MlLJV2FPT0WU
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\aTWM2OD16M{KuOFUhdk1? MoDDV2FPT0WU
EW-18 M1HyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjHbm9SUUN3ME24N|IvQTZibl2= NEHPeYVUSU6JRWK=
P30-OHK MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfGZWVKSzVyPUizOU44KG6P NGDqbGtUSU6JRWK=
D-566MG NYG4WmZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf0XJNKSzVyPUizPE43OiCwTR?= M{XmWXNCVkeHUh?=
HSC-4 NFL3WFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TBUWlEPTB;OES2MlUyKG6P MYfTRW5ITVJ?
QIMR-WIL MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TOV2lEPTB;OE[yMlA{KG6P MkLWV2FPT0WU
SW954 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLWPHVGUUN3ME24OlMvOTZibl2= MofqV2FPT0WU
HGC-27 M3\V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInZbZhKSzVyPUi3Nk4{PCCwTR?= M{LI[nNCVkeHUh?=
HH NXjGZll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LlNWlEPTB;OEm0MlEzKG6P M1ztfXNCVkeHUh?=
KE-37 M2LP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13KbGlEPTB;OEm0MlYzKG6P MVrTRW5ITVJ?
SK-N-DZ M{TMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTlyMD60N{BvVQ>? NWD5RWtDW0GQR1XS
J-RT3-T3-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rrZmlEPTB;OUGwMlQ6KG6P MXTTRW5ITVJ?
A427 NEjESGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6xTWM2OD17MkCuPFQhdk1? M1e4PXNCVkeHUh?=
ECC10 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\qdIVKSzVyPUm0OU45PyCwTR?= NE\DZopUSU6JRWK=
EW-1 NIjxUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvpdJBYUUN3ME25OFcvOjZibl2= NVmyXVQ3W0GQR1XS
MIA-PaCa-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f6O2lEPTB;OUS5MlEzKG6P M4T5U3NCVkeHUh?=
HCC2218 NXjrU|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfkTWM2OD17NUiuOFghdk1? Ml34V2FPT0WU
HAL-01 NY\hPW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVruSHlZUUN3ME25OlgvODRibl2= MonNV2FPT0WU
RD NF\UVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfsTWM2OD17N{SuOFUhdk1? NGnXW|BUSU6JRWK=
SK-N-AS MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\rUnhKSzVyPUm4PE4yKG6P M3vJOXNCVkeHUh?=
ML-2 M2jvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHhcXN7UUN3ME2xMlAxPDB5IN88US=> Mn7PV2FPT0WU
MEL-HO NGPSbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7OZlhKSzVyPUGuNFA2QDJizszN NFzrXpRUSU6JRWK=
MS-1 M3zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jZRmlEPTB;MT6wNFYyPyEQvF2= MnTKV2FPT0WU
NCI-SNU-1 NYjadVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMEKzN|Eh|ryP MYTTRW5ITVJ?
8505C MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwMEKzN|Eh|ryP NGLhVJhUSU6JRWK=
MN-60 M1KxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfaTWM2OD1zLkCyOlgh|ryP MX7TRW5ITVJ?
SAS NGnQVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLETWM2OD1zLkC0NFgyKM7:TR?= M3nofHNCVkeHUh?=
EFM-19 NGizT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwMES4O|kh|ryP NWjFWHBDW0GQR1XS
Ca9-22 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXMSXY4UUN3ME2xMlA2OTB5IN88US=> MkHNV2FPT0WU
NBsusSR M3jIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fXN2lEPTB;MT6wOVE3PiEQvF2= NF;0WXVUSU6JRWK=
NB13 NXjqc4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXobYFKSzVyPUGuNFU2ODFizszN MWnTRW5ITVJ?
SF295 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HTVmlEPTB;MT6wOlYzPCEQvF2= NETNZnlUSU6JRWK=
U-2-OS M4m0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrnTWM2OD1zLkC3PVEyKM7:TR?= NUnBU3FOW0GQR1XS
NCI-H526 NHXw[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HlXWlEPTB;MT6wPFI6OSEQvF2= NWe2OlY2W0GQR1XS
KMOE-2 M2e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7STo45UUN3ME2xMlA6PDJ{IN88US=> NULIXGlIW0GQR1XS
RCM-1 NG\kV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwMUKxNFIh|ryP NVTNPG1KW0GQR1XS
MC116 NX\vSmtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfvXYtTUUN3ME2xMlE{PjJzIN88US=> NVLJZ4J1W0GQR1XS
NCI-H1092 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfiXolrUUN3ME2xMlE2PDB4IN88US=> M4jtW3NCVkeHUh?=
EW-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3q[GZOUUN3ME2xMlE4OjF{IN88US=> MXzTRW5ITVJ?
HCT-116 NVz5boZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG3WWVyUUN3ME2xMlE4PzVizszN M2XCfHNCVkeHUh?=
MC-IXC M2LSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvoc3ZKSzVyPUGuNVc5QDFizszN MUjTRW5ITVJ?
LB1047-RCC M4S2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu4VGJ{UUN3ME2xMlE5OzF{IN88US=> NHP0SHVUSU6JRWK=
VM-CUB-1 NE\NOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMUmxNFgh|ryP MUjTRW5ITVJ?
NB5 NWjNd|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LibWlEPTB;MT6xPVg2PiEQvF2= MWHTRW5ITVJ?
SKG-IIIa NYfmO41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHmTWM2OD1zLkKzOFY1KM7:TR?= MnuzV2FPT0WU
HO-1-N-1 NVPNZ|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLSGlEPTB;MT6yN|g{PSEQvF2= MYLTRW5ITVJ?
EFO-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHracHlKSzVyPUGuNlUxPDNizszN NXy4clNKW0GQR1XS
MHH-NB-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD1zLkK4N|I6KM7:TR?= NV\JVZhlW0GQR1XS
SW620 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHWTWM2OD1zLkK5NFE5KM7:TR?= NVeyXVRJW0GQR1XS
MOLT-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSxTWM2OD1zLkK5O|k4KM7:TR?= MYnTRW5ITVJ?
NTERA-S-cl-D1 NGLNVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLSNZhKSzVyPUGuN|E4PjFizszN NUDSXolkW0GQR1XS
VA-ES-BJ M2nRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH6dG9KSzVyPUGuN|I1PzdizszN NVLZTYxVW0GQR1XS
HCC1419 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7kTWM2OD1zLkO0NFI4KM7:TR?= NH\HO2ZUSU6JRWK=
NCI-H69 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzRXWxKUUN3ME2xMlM1OTF{IN88US=> NEjmZo9USU6JRWK=
DEL NWH1W5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoThTWM2OD1zLkO1NVYzKM7:TR?= MlTuV2FPT0WU
LXF-289 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwM{WyOEDPxE1? NGLCcXNUSU6JRWK=
EW-11 NEOyTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwM{[wNlYh|ryP NFjLVWtUSU6JRWK=
KP-4 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TKcGlEPTB;MT6zO|A5PSEQvF2= MnPqV2FPT0WU
NOS-1 M1fEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TrS2lEPTB;MT60NVE6PCEQvF2= M{XMeHNCVkeHUh?=
SK-NEP-1 NYK5TW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorETWM2OD1zLkSxOlk{KM7:TR?= NHW3T3FUSU6JRWK=
LAMA-84 NVLO[ZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwNEO5OFUh|ryP NVzuSnRqW0GQR1XS
ES5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPNeHBKSzVyPUGuOFQ{KM7:TR?= M{DGfHNCVkeHUh?=
HuO9 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;uUG9KSzVyPUGuOFU{PjJizszN MWjTRW5ITVJ?
COLO-684 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnncpgyUUN3ME2xMlQ3OTF6IN88US=> M1nxeXNCVkeHUh?=
EW-24 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHQR4RKUUN3ME2xMlQ3PTNzIN88US=> MkLWV2FPT0WU
BV-173 NF3aUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPL[3lWUUN3ME2xMlQ4OjlzIN88US=> Mn6wV2FPT0WU
NCI-H1770 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDhfYViUUN3ME2xMlQ5PTN4IN88US=> MmPMV2FPT0WU
HuP-T4 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1PGlKSzVyPUGuOFk{KM7:TR?= M{LicHNCVkeHUh?=
TYK-nu MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkiwTWM2OD1zLkS5PFUyKM7:TR?= Mk[1V2FPT0WU
YH-13 NUXjOGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i4RWlEPTB;MT60PVg6PCEQvF2= MkTxV2FPT0WU
H4 NXTJNJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwNUC5NVIh|ryP M121[nNCVkeHUh?=
OVCAR-8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDqZXlKSzVyPUGuOVQ1PzdizszN NVXPS3g{W0GQR1XS
NCI-H23 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwNUS2OFUh|ryP M3LKVHNCVkeHUh?=
ES7 M2TpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1VXo4UUN3ME2xMlU1Pzd|IN88US=> M1uwUnNCVkeHUh?=
COR-L88 NEXFS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\5OmpKSzVyPUGuOVY1OjRizszN NGXkNZZUSU6JRWK=
TI-73 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwNUmwOkDPxE1? NIO5[3VUSU6JRWK=
RT-112 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmxdGlKSzVyPUGuOVkzQDRizszN NUXwSnA1W0GQR1XS
HuO-3N1 M{PIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLaTWM2OD1zLkW5N|g2KM7:TR?= NUH2SpZbW0GQR1XS
HC-1 M2LOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljxTWM2OD1zLkW5PFY3KM7:TR?= NUjrR5VDW0GQR1XS
HT55 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTBdXBqUUN3ME2xMlY2OTNzIN88US=> MYDTRW5ITVJ?
IA-LM MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMTVRKUUN3ME2xMlY6Ojd6IN88US=> NETRdJFUSU6JRWK=
EM-2 NV;mfG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzTWM2OD1zLkewNFE1KM7:TR?= MULTRW5ITVJ?
MHH-ES-1 NFvldndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf0TWM2OD1zLkewOFM2KM7:TR?= MnroV2FPT0WU
CAL-27 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7FT2JKSzVyPUGuO|A3OjFizszN M4LFXHNCVkeHUh?=
COLO-800 NIDWVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwN{GxO|kh|ryP MUDTRW5ITVJ?
HCE-T M{Hnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHETWM2OD1zLkexOUDPxE1? M3\IfHNCVkeHUh?=
CAMA-1 M4HrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn72TWM2OD1zLkexPVcyKM7:TR?= NVflTZliW0GQR1XS
LOXIMVI NYizOZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK5UVB7UUN3ME2xMlczOTFizszN MXXTRW5ITVJ?
NH-12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPxZYhzUUN3ME2xMlczPjlzIN88US=> M2HjUXNCVkeHUh?=
TCCSUP NHjDd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDvUFJxUUN3ME2xMlczQDJ7IN88US=> MnvPV2FPT0WU
MDA-MB-361 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL3TWM2OD1zLkezNVU4KM7:TR?= NHr0O|JUSU6JRWK=
EW-16 M2nwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPGV2lGUUN3ME2xMlc1OTB5IN88US=> NWfPUoJPW0GQR1XS
SNU-423 NFXPUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwN{W4Nlch|ryP NV22d|FkW0GQR1XS
Daoy NIXGc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEflPVhKSzVyPUGuO|Y{OTlizszN NH7weo5USU6JRWK=
ES4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLubXdKSzVyPUGuO|g4PDFizszN MYrTRW5ITVJ?
PFSK-1 NXL5V5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwWWlEPTB;MT64NFM4KM7:TR?= NWrBd3hqW0GQR1XS
ES3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PUVGlEPTB;MT64NlY5OSEQvF2= M1LVVnNCVkeHUh?=
ONS-76 NXPBeYhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0fmlEPTB;MT64Nlg6PyEQvF2= M3fyS3NCVkeHUh?=
JVM-3 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwOEW0OVEh|ryP M{HoS3NCVkeHUh?=
OS-RC-2 NUXqOmZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfOfXVKSzVyPUGuPFcyPTFizszN NFroR4pUSU6JRWK=
COLO-320-HSR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0TWM2OD1zLki4NVk4KM7:TR?= MkP6V2FPT0WU
HN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD1zLki4O|I2KM7:TR?= MkH1V2FPT0WU
HT MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHnNVI4UUN3ME2xMlg5QTR5IN88US=> MmO1V2FPT0WU
LoVo NF7HZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnud|dKSzVyPUGuPFk5OSEQvF2= NFzXfFZUSU6JRWK=
CGTH-W-1 NFqzd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW0VIhKSzVyPUGuPFk6PDZizszN M1TwbHNCVkeHUh?=
NB6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwOUGyPVgh|ryP MUTTRW5ITVJ?
EW-22 NGP4ZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\YdY5yUUN3ME2xMlkzQDh5IN88US=> NVXB[oFiW0GQR1XS
ES6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfBd5hsUUN3ME2xMlk{PjNzIN88US=> M2W5bHNCVkeHUh?=
SCC-15 NWH1UpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMSGlEPTB;MT65N|gyQSEQvF2= NWTySWx1W0GQR1XS
HL-60 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXoXWdKSzVyPUGuPVM6ODJizszN M3TORXNCVkeHUh?=
human HOP-92 M3rPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf4OZl[UUN3ME2xMlk1ODZ3IN88US=> NIXZWVhUSU6JRWK=
SW626 NYHLO5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1bmlEPTB;MT65OFg6QSEQvF2= NV\0SIdUW0GQR1XS
HEC-1 NIfDfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTndGdqUUN3ME2xMlk2OzZizszN NEX4O5NUSU6JRWK=
LB2241-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5fmlEPTB;MT65PFI{OSEQvF2= MmrlV2FPT0WU
Ramos-2G6-4C10 M{frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;mN2lEPTB;MT65PVQ6OyEQvF2= MnXtV2FPT0WU
A101D NWrHXI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXwOJJ4UUN3ME2yMlIxOzB|IN88US=> MWnTRW5ITVJ?
NCI-H446 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;BV5NyUUN3ME2yMlA1PTl7IN88US=> MU\TRW5ITVJ?
SBC-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\qeGlEPTB;Mj6wOlE1PyEQvF2= NIPQ[|hUSU6JRWK=
HOS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z1OmlEPTB;Mj6wO|Y2OyEQvF2= MWTTRW5ITVJ?
K5 NH3NUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLyb5VlUUN3ME2yMlA4QDFzIN88US=> MYfTRW5ITVJ?
HLE MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTXOIJ{UUN3ME2yMlA5PTJ7IN88US=> NF\qXHRUSU6JRWK=
HSC-2 NW\KVFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJwMUK4PVgh|ryP NV3PbWR6W0GQR1XS
LCLC-97TM1 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGyOldKSzVyPUKuNVQ2QDNizszN NEXmR2tUSU6JRWK=
DMS-273 NYjDXVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4dpBKSzVyPUKuNVQ5OzdizszN MnnnV2FPT0WU
TE-8 NIDnflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXXPItKSzVyPUKuNVU4PjVizszN NVrOXlRlW0GQR1XS
DSH1 M{nyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvXd2RuUUN3ME2yMlE3Ozl6IN88US=> NIS0PIZUSU6JRWK=
CAL-51 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwMU[2PVkh|ryP NWizPWxCW0GQR1XS
IST-SL1 M1LoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPrTWM2OD1{LkG2PFQ1KM7:TR?= MX;TRW5ITVJ?
GCT NH\3fVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsdFJtUUN3ME2yMlE4PzdizszN NVryPZBoW0GQR1XS
SW948 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwMUi0OVYh|ryP M2PSU3NCVkeHUh?=
NOMO-1 NWe3[2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwMUmzNVch|ryP M4PjNHNCVkeHUh?=
C8166 NVvuN5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jBdmlEPTB;Mj6yNVM{PCEQvF2= M{\ZTXNCVkeHUh?=
OC-314 NHvZ[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJwMkOyOVkh|ryP NEfidIZUSU6JRWK=
CAL-39 NIXYfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwMkO2NlYh|ryP NVXzO|RCW0GQR1XS
MDA-MB-453 NWfEUmNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfrSW5KSzVyPUKuNlQzPzVizszN M1y1TXNCVkeHUh?=
A673 NHG0TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPHTWM2OD1{LkK1PFYzKM7:TR?= MoDuV2FPT0WU
HTC-C3 NG\FN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzuTWM2OD1{LkK2PFUh|ryP MmftV2FPT0WU
NCI-H1666 NV3hZ2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4TGlEPTB;Mj6yPFEyOSEQvF2= NYrRbmhNW0GQR1XS
PSN1 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4bGlEPTB;Mj6yPFkyOyEQvF2= NXLDdndDW0GQR1XS
GI-1 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml24TWM2OD1{LkOwOVQ{KM7:TR?= MYHTRW5ITVJ?
HuH-7 M3HhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwM{C2N|ch|ryP NGjwO2xUSU6JRWK=
JAR NFiyfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XlT2lEPTB;Mj6zNVk5PyEQvF2= MmnuV2FPT0WU
5637 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfDTWM2OD1{LkOyNVI6KM7:TR?= MVXTRW5ITVJ?
GB-1 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr4VFFKSzVyPUKuN|I{OzVizszN NVHNNpNuW0GQR1XS
KP-N-YS NUfMcZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwM{K2NVUh|ryP NVrhWo9PW0GQR1XS
OAW-42 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXPTWM2OD1{LkOzOFE3KM7:TR?= M17PZnNCVkeHUh?=
8-MG-BA MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwM{O5NFYh|ryP M33odHNCVkeHUh?=
RH-18 NI[2PWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHnTWM2OD1{LkO1NFIzKM7:TR?= Mn24V2FPT0WU
NCI-H1155 M3Wy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJwM{[3NlUh|ryP NF7CTXdUSU6JRWK=
NB17 M1K4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFdmlEPTB;Mj6zPFI1OyEQvF2= MVPTRW5ITVJ?
NCI-H1437 M175V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPjR3JlUUN3ME2yMlQyQDd|IN88US=> M3e4V3NCVkeHUh?=
SN12C MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwNEOyNVQh|ryP MXfTRW5ITVJ?
HSC-3 NVTLO4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPHXnkyUUN3ME2yMlQ1PTB7IN88US=> NWS4em97W0GQR1XS
GAMG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULaZ5k2UUN3ME2yMlQ1PTZzIN88US=> M1raNXNCVkeHUh?=
HT-1080 NUDtW|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO2XJo2UUN3ME2yMlQ1QDZ2IN88US=> M{D0SHNCVkeHUh?=
A549 M2S2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPJPG5PUUN3ME2yMlQ1QDl|IN88US=> MXPTRW5ITVJ?
KNS-62 NUD0S4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;JTWM2OD1{LkS1NFYyKM7:TR?= M3frO3NCVkeHUh?=
YKG-1 M2XVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r4ZWlEPTB;Mj60OVQ{PyEQvF2= MnrpV2FPT0WU
LU-134-A NES1NFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofJTWM2OD1{LkS3NFA5KM7:TR?= NITKWpdUSU6JRWK=
FADU M2Pre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFPWlEPTB;Mj60O|E3OiEQvF2= MoPDV2FPT0WU
TGBC11TKB NIjhblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwNEexO|ch|ryP M3vqVnNCVkeHUh?=
HT-3 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi0ZZk6UUN3ME2yMlQ6PTN3IN88US=> M3XPTXNCVkeHUh?=
NCI-H2170 NH3HV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDK[mEzUUN3ME2yMlUxPTR7IN88US=> NWPnWlRwW0GQR1XS
Mo-T NFXJNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny0TWM2OD1{LkWwPVI4KM7:TR?= M2CzR3NCVkeHUh?=
CCRF-CEM MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7sTWM2OD1{LkWzNFQ{KM7:TR?= NIKxOFNUSU6JRWK=
KU-19-19 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLWbo5KSzVyPUKuOVM2OTNizszN NXnJNnJxW0GQR1XS
NCI-H1048 NX7ZVWU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnaTIxVUUN3ME2yMlU2ODJ3IN88US=> NVHhcHRKW0GQR1XS
KOSC-2 M4G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzTTWM2OD1{LkW2NFc3KM7:TR?= NYfJdY15W0GQR1XS
A431 NX6ydHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjVIZRUUN3ME2yMlU3OzN3IN88US=> NEjIWHdUSU6JRWK=
COR-L23 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO0SmY3UUN3ME2yMlU5PTZ4IN88US=> NIf3O4pUSU6JRWK=
MKN28 NHOycJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntbndVUUN3ME2yMlU6ODN5IN88US=> NEH1bpRUSU6JRWK=
22RV1 NX[4OJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHtbGExUUN3ME2yMlU6Ojd2IN88US=> MYTTRW5ITVJ?
ABC-1 NU\RPYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLxUpBKSzVyPUKuOlA1PiEQvF2= NVT5TZRYW0GQR1XS
NCI-H2126 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPDTWM2OD1{Lk[wPVg1KM7:TR?= M2O4[nNCVkeHUh?=
DoTc2-4510 NHLRU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPoUGw{UUN3ME2yMlYzOTh3IN88US=> NE\LSphUSU6JRWK=
SCC-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD1{Lk[zNFEzKM7:TR?= M1fifnNCVkeHUh?=
NCI-H661 NXe0fmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrPTWM2OD1{Lk[0NFg2KM7:TR?= MlW5V2FPT0WU
RPMI-2650 M2n2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LEe2lEPTB;Mj62OFE1OyEQvF2= M1HQSHNCVkeHUh?=
NCI-H510A MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNkS0NlYh|ryP Mle5V2FPT0WU
BPH-1 NHP2UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLaUmNKSzVyPUKuOlU5PSEQvF2= MkDlV2FPT0WU
M14 NXiwPZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwNk[5PVMh|ryP MVfTRW5ITVJ?
G-402 M1n6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPidZRKSzVyPUKuO|A1PTFizszN M1TQWHNCVkeHUh?=
AsPC-1 NYTPRXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwN{GxO{DPxE1? MmrhV2FPT0WU
NB12 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HRWmlEPTB;Mj63NVcyKM7:TR?= NVzidJM4W0GQR1XS
SK-HEP-1 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTRTlRKSzVyPUKuO|Q{QTFizszN M{XVNHNCVkeHUh?=
U-266 NF7JWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfoOVZKSzVyPUKuO|cyOjFizszN NYPvTFhCW0GQR1XS
AM-38 NF\MR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rsOGlEPTB;Mj63O|M2PSEQvF2= MY\TRW5ITVJ?
PC-14 M3nIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwOEC1NUDPxE1? MlrpV2FPT0WU
EGI-1 NVKwUHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ySnZKSzVyPUKuPFE4PDNizszN NFu0cG5USU6JRWK=
LS-411N NWjOVWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jG[mlEPTB;Mj64NlM{KM7:TR?= M3zhXnNCVkeHUh?=
BFTC-905 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwOEW1NlMh|ryP Mn6zV2FPT0WU
CaR-1 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvvfFV2UUN3ME2yMlg3KM7:TR?= NF7Cd45USU6JRWK=
NCI-H292 NVH4WI5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pb3dKSzVyPUKuPFY2QTZizszN NXGwfIp5W0GQR1XS
8305C NHLDPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwOE[2OFUh|ryP MXPTRW5ITVJ?
SNU-449 NUHLbm46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXhTWM2OD1{Lki5NVgzKM7:TR?= MmntV2FPT0WU
LCLC-103H NGPLOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwOUC0N|gh|ryP NYTsblN1W0GQR1XS
SW1573 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXuTYxKSzVyPUKuPVYxQDJizszN NGmwUI5USU6JRWK=
MLMA M4fkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLpTWM2OD1{Lkm2O|E4KM7:TR?= M1XWXnNCVkeHUh?=
NCI-H1355 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf1VYdDUUN3ME2zMlAxPzl4IN88US=> M174cHNCVkeHUh?=
RMG-I M1[2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTNwMEK1PVIh|ryP NHz3[|JUSU6JRWK=
BB65-RCC M3vlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjiT|RKSzVyPUOuNFM{OTRizszN MYXTRW5ITVJ?
PC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjHbZR{UUN3ME2zMlA{QDd2IN88US=> NVqyZVlUW0GQR1XS
SF268 M4rNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMES1NlMh|ryP NEe0bmVUSU6JRWK=
NCI-H810 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqSndYUUN3ME2zMlA1QDJ|IN88US=> Mo\GV2FPT0WU
MEG-01 M1HNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G1TWlEPTB;Mz6wOlE3PCEQvF2= NHPoZpBUSU6JRWK=
SW13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ywd2lEPTB;Mz6wO|g1PyEQvF2= MXLTRW5ITVJ?
RH-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwMUCyO|gh|ryP NGryPVhUSU6JRWK=
GT3TKB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vvXmlEPTB;Mz6xNVI5OyEQvF2= M{WzZXNCVkeHUh?=
TK10 NGfK[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwMUO3NlQh|ryP MVPTRW5ITVJ?
T-24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwMUWwO{DPxE1? M3WxSnNCVkeHUh?=
A498 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjQTWM2OD1|LkKwPFcyKM7:TR?= MlryV2FPT0WU
GR-ST MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\STWM2OD1|LkKyNVM6KM7:TR?= NX7tUJREW0GQR1XS
LB2518-MEL NEjSdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzYXVdKSzVyPUOuNlI{QThizszN NVrFS4ViW0GQR1XS
T47D M4Dpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMkO2Nlch|ryP Mlv6V2FPT0WU
NCI-H1651 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\DOWlEPTB;Mz6yOFY1PCEQvF2= M2PB[nNCVkeHUh?=
EC-GI-10 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Ve25CUUN3ME2zMlI3OTV|IN88US=> NVfrRZloW0GQR1XS
HT-29 NYLXT457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwMk[2NVQh|ryP M3HHR3NCVkeHUh?=
GI-ME-N NVzNOoliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK1TWM2OD1|LkK5OVEyKM7:TR?= MnfkV2FPT0WU
SW756 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHTWM2OD1|LkK5OlI6KM7:TR?= MmTxV2FPT0WU
RKO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\3bGlEPTB;Mz6zNFc2PyEQvF2= NI\4VGVUSU6JRWK=
NCI-H1563 M{fGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnROYxKSzVyPUOuN|MxOThizszN M2rFOnNCVkeHUh?=
DJM-1 NVi2RWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmwOlJKSzVyPUOuN|c3PzRizszN M4XofXNCVkeHUh?=
L-428 NYLpTFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfneWVGUUN3ME2zMlQxODR3IN88US=> Mn2wV2FPT0WU
NCI-H2122 NXX0fmVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvFc3NoUUN3ME2zMlQyOzF{IN88US=> NHviZlVUSU6JRWK=
Ca-Ski MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNwNEW0N{DPxE1? NED6[VNUSU6JRWK=
639-V Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zTWM2OD1|LkS2NFU4KM7:TR?= NF[5ZY5USU6JRWK=
SW1116 M3;qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr6TWM2OD1|LkS2NlY6KM7:TR?= M2fiXXNCVkeHUh?=
DMS-114 NUHxOZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzT[lBKSzVyPUOuOFcxPjZizszN M{HicHNCVkeHUh?=
MZ2-MEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nSemlEPTB;Mz60O|Y5OSEQvF2= MYnTRW5ITVJ?
COLO-829 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jPR2lEPTB;Mz61NFA4OyEQvF2= NXvYfXMyW0GQR1XS
J82 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNwNUC1O{DPxE1? MlzBV2FPT0WU
EW-13 M{TKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvoTWM2OD1|LkWyOVEh|ryP NWL4T2t3W0GQR1XS
RXF393 NVT5NI85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrS[XFxUUN3ME2zMlU{Ojl2IN88US=> MmXFV2FPT0WU
CAL-62 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDBTWM2OD1|LkW0OVE1KM7:TR?= MXHTRW5ITVJ?
OCUB-M MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWc|dnUUN3ME2zMlU1PjZ3IN88US=> NX\xbGlyW0GQR1XS
BT-474 NX7XfXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLITotHUUN3ME2zMlY{OzFizszN Ml\PV2FPT0WU
KYSE-180 M{ewN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPS[lZ5UUN3ME2zMlY{Ozd{IN88US=> NU\YNHBJW0GQR1XS
NCI-H650 M33uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfwTWM2OD1|Lk[0Nlg4KM7:TR?= M{\1UnNCVkeHUh?=
Detroit562 M3zUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwNkWwNlIh|ryP NX;I[mpDW0GQR1XS
SW48 NIK2N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLIUVZzUUN3ME2zMlY2PjV5IN88US=> NFjZNXZUSU6JRWK=
KYSE-450 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXBWVBKSzVyPUOuOlg2QDJizszN MX3TRW5ITVJ?
KYSE-510 NH;kW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzsOZBKSzVyPUOuO|IyQDFizszN M2[ycHNCVkeHUh?=
GP5d NF\RNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvjS3h1UUN3ME2zMlczQTVizszN MXvTRW5ITVJ?
RPMI-7951 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvIRpdHUUN3ME2zMlc1PzJ|IN88US=> MonCV2FPT0WU
Becker M2\Pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMTWM2OD1|Lke1NFEzKM7:TR?= MXrTRW5ITVJ?
WM-115 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPITWM2OD1|Lke4NVk2KM7:TR?= NYqwVXVKW0GQR1XS
G-401 NV62ZYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPGTWM2OD1|Lke5NFg2KM7:TR?= NVnpNYlyW0GQR1XS
PANC-08-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z5eGlEPTB;Mz63PVYxOiEQvF2= NVz5VmtNW0GQR1XS
SW982 NX3Id2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwOEC1OVEh|ryP M2KyTHNCVkeHUh?=
D-263MG NGfZVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD1|LkiyNFUyKM7:TR?= MojLV2FPT0WU
KM-H2 M{T0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkTWM2OD1|LkiyOlI1KM7:TR?= MWPTRW5ITVJ?
SK-MEL-3 M2HwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyxW3VRUUN3ME2zMlgzQDRzIN88US=> NX\selJoW0GQR1XS
NCI-H1581 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3oTWM2OD1|Lki0OFg5KM7:TR?= M{faRnNCVkeHUh?=
LS-123 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj5XoM3UUN3ME2zMlg4QTB7IN88US=> MX\TRW5ITVJ?
CAKI-1 M1r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHhTWM2OD1|Lki5NFUzKM7:TR?= MUXTRW5ITVJ?
MEL-JUSO NY\XPYFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvpemJKSzVyPUOuPFkyPTNizszN NIC0TnpUSU6JRWK=
HCE-4 NFjBSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTYOJV4UUN3ME2zMlkyPjZ|IN88US=> NGf5NnNUSU6JRWK=
TE-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PFTGlEPTB;Mz65NlAyKM7:TR?= NWjDeYc2W0GQR1XS
OVCAR-4 M1fKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;nTWM2OD1|LkmyPFg6KM7:TR?= NFPUTYVUSU6JRWK=
ETK-1 NUXue45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK2RpZTUUN3ME2zMlk1PjN3IN88US=> Mo\QV2FPT0WU
A2780 M{nvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsWG1KSzVyPUSuNFU6PjZizszN MnjoV2FPT0WU
LU-65 NHLje5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwMEe2N|Mh|ryP NYDsOpV[W0GQR1XS
BHY MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCS4l[UUN3ME20MlEzPDl3IN88US=> NVmwc3JuW0GQR1XS
COR-L105 M2fwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhdGlEPTB;ND6xN|A2OSEQvF2= M3LRUHNCVkeHUh?=
CAL-12T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTuVY11UUN3ME20MlE{OTB|IN88US=> MYjTRW5ITVJ?
SCH Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;wcZM6UUN3ME20MlE2PzR|IN88US=> NVL0UlBsW0GQR1XS
CW-2 NF;DZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T5c2lEPTB;ND6xPVAxOSEQvF2= NHnYRXBUSU6JRWK=
HCC1806 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTUVFFlUUN3ME20MlIxOzF{IN88US=> NITGb4VUSU6JRWK=
KP-N-YN Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jySGlEPTB;ND6yNFkzPyEQvF2= M3H1W3NCVkeHUh?=
T98G NX7PZ2x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofyTWM2OD12LkKyNVU4KM7:TR?= M3G0fHNCVkeHUh?=
CAL-54 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXsOZVmUUN3ME20MlIzOzhzIN88US=> NFnNTHZUSU6JRWK=
CAL-33 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK5OIRVUUN3ME20MlI{ODZ2IN88US=> MlmzV2FPT0WU
SNU-C2B NVvnU4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTRwMkS3Olkh|ryP NX;LeHBVW0GQR1XS
NUGC-3 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRRWlEPTB;ND6yOVUxPSEQvF2= NYTvSG1wW0GQR1XS
DOK NH3U[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TSZ2lEPTB;ND6yOlU6OyEQvF2= MonDV2FPT0WU
MMAC-SF NIHCWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpbmVKSzVyPUSuNlY5PTlizszN NGD6RWxUSU6JRWK=
KYSE-70 NFHtc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3seJg2UUN3ME20MlI6OzRizszN NUPifYhtW0GQR1XS
A204 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwM{W4NFMh|ryP NFXTeWJUSU6JRWK=
SCC-25 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TpeGlEPTB;ND6zOVgyQSEQvF2= NGLqUFJUSU6JRWK=
EPLC-272H NEjLNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;vfWlEPTB;ND6zPFk2KM7:TR?= NEn4UJdUSU6JRWK=
CAL-120 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwM{i5PVIh|ryP NHHxbnVUSU6JRWK=
LS-513 NF76eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m3VWlEPTB;ND60NlE6QCEQvF2= NXrVO4NKW0GQR1XS
CAPAN-1 NH2wZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFviZmlKSzVyPUSuOFI{QDJizszN M1XNN3NCVkeHUh?=
ESS-1 M3LNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPVoZKSzVyPUSuOFI4OjRizszN NXLrPYxoW0GQR1XS
GMS-10 M1LSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzFTWM2OD12LkSyPFE6KM7:TR?= NID3ZpFUSU6JRWK=
NCI-N87 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjGVWRKSzVyPUSuOVA5PjhizszN NIPXWW1USU6JRWK=
HMV-II NFWz[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHmTWM2OD12LkWxO|Mh|ryP NIPHUYhUSU6JRWK=
COLO-741 NXO4bFA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvkTWM2OD12LkW1PVk1KM7:TR?= NIjse|dUSU6JRWK=
MKN45 NEjkSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvLNIpKSzVyPUSuOVc4OzJizszN MWLTRW5ITVJ?
OAW-28 NY\QNI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwNUizPVgh|ryP NYDBTXNtW0GQR1XS
OCI-AML2 NFLQZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHicmJKSzVyPUSuOlUzOzhizszN M1m1dXNCVkeHUh?=
MDA-MB-231 Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPd3RjUUN3ME20MlcxOjR|IN88US=> MUDTRW5ITVJ?
NCI-H1648 NWnOe3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwN{KyO|Mh|ryP NFjnbWNUSU6JRWK=
NCI-H1792 NXr2VIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwN{[xNFch|ryP NXnlTJFRW0GQR1XS
GCIY MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDpdZVKSzVyPUSuO|c1OjRizszN NGDrN2FUSU6JRWK=
Hs-578-T M2LkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\STmlEPTB;ND63O|Y2PSEQvF2= NIXQUo5USU6JRWK=
SW962 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPmNG1KSzVyPUSuO|gxOTFizszN MVLTRW5ITVJ?
NCI-H630 NFv4cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvWGdKSzVyPUSuO|gxQDFizszN M2PDOXNCVkeHUh?=
786-0 NVLlN3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTRwN{i3O|Mh|ryP MV7TRW5ITVJ?
FTC-133 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrRTWM2OD12Lke5NlY{KM7:TR?= MVPTRW5ITVJ?
BT-20 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLtTWM2OD12Lke5OFI6KM7:TR?= M2TS[3NCVkeHUh?=
Mewo MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRwOEG3OFch|ryP M2LwSnNCVkeHUh?=
SW780 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHzN2FSUUN3ME20Mlg2PzZ4IN88US=> NWjiWY5JW0GQR1XS
OE33 NFqwd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVizdmg6UUN3ME20Mlg4PzF|IN88US=> MYHTRW5ITVJ?
HCC1569 NVe0bll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CwW2lEPTB;ND64PFQ2QCEQvF2= MoPiV2FPT0WU
TE-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3DRW9zUUN3ME20Mlk{QTd5IN88US=> MVLTRW5ITVJ?
SK-N-FI NUjYdlk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2OmlEPTB;ND65OFQzOSEQvF2= MYDTRW5ITVJ?
PANC-03-27 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTaNXljUUN3ME20Mlk6QTZ{IN88US=> Mle1V2FPT0WU
MCF7 NVrSeldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\PTWM2OD13LkCwO|M5KM7:TR?= MoezV2FPT0WU
UACC-257 M1XhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XTbmlEPTB;NT6wNlg1PSEQvF2= M4f3VnNCVkeHUh?=
SW1088 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXbohZUUN3ME21MlAzQTR2IN88US=> NUP4Oo5XW0GQR1XS
A704 NV7x[I5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTVwMEOwOkDPxE1? NI\NXoFUSU6JRWK=
A2058 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTPTWM2OD13LkC1PVA5KM7:TR?= NX;oUpN2W0GQR1XS
Calu-3 NHiwb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\GZmxKSzVyPUWuNFY1PTJizszN NUDlPW9PW0GQR1XS
RERF-LC-MS MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3jbYhRUUN3ME21MlA3QTB|IN88US=> MkfSV2FPT0WU
AU565 M{n2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjuTWM2OD13LkC5O|AzKM7:TR?= Mkj1V2FPT0WU
DMS-79 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zxVWlEPTB;NT6xN|g5OyEQvF2= NITaXo1USU6JRWK=
DK-MG MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24UIp6UUN3ME21MlE5PDN6IN88US=> NXG5cldGW0GQR1XS
HuCCT1 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfP[lhKSzVyPUWuNlM5PTZizszN MXLTRW5ITVJ?
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HxPWlEPTB;NT6yOFk5PyEQvF2= NVK1[2UxW0GQR1XS
M059J NFrVR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r0SmlEPTB;NT6yOVc3KM7:TR?= MUjTRW5ITVJ?
COLO-792 M3jhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljoTWM2OD13LkK2N|U3KM7:TR?= Mmi5V2FPT0WU
SF539 NXHZSZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHUTWM2OD13LkK2OlMzKM7:TR?= M{fLXnNCVkeHUh?=
SK-UT-1 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHDTWM2OD13LkK3O|UyKM7:TR?= M2\W[HNCVkeHUh?=
NCI-H1703 NYX5c5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwM{W4NlYh|ryP MUPTRW5ITVJ?
SW837 NGLXdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13tfGlEPTB;NT6zO|g4QCEQvF2= M4\rcnNCVkeHUh?=
U251 NFfuSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkntTWM2OD13LkO5NFk3KM7:TR?= M33m[HNCVkeHUh?=
SW1710 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi3cFFKSzVyPUWuOFE2PTRizszN MWHTRW5ITVJ?
NCI-H1299 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74TppKSzVyPUWuOFY{OzVizszN M{LWbnNCVkeHUh?=
RVH-421 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnIVG5KSzVyPUWuOFk6ODhizszN MWnTRW5ITVJ?
UM-UC-3 NHTXdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\abGVIUUN3ME21MlYzPjVzIN88US=> Mnz1V2FPT0WU
MDA-MB-175-VII M3v0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7qTWM2OD13Lk[0NFQyKM7:TR?= NITn[2tUSU6JRWK=
KYSE-270 NWDMclRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXYTWM2OD13Lk[2NFMyKM7:TR?= NWLk[FI{W0GQR1XS
COLO-668 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi4TWM2OD13LkexN|Ih|ryP NIrhRY9USU6JRWK=
LN-405 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLJTI5KSzVyPUWuO|MxQDVizszN NH;0fmpUSU6JRWK=
HT-1376 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTVwN{iwOVIh|ryP MVfTRW5ITVJ?
769-P M3\QSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwOE[3NVgh|ryP NVTNeG03W0GQR1XS
HuP-T3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD13Lki4Olc4KM7:TR?= NYjrWW54W0GQR1XS
MDA-MB-415 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXntUplEUUN3ME21MlkzOTN7IN88US=> MWXTRW5ITVJ?
MKN7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTVwOUi4JO69VQ>? NU\OWGtDW0GQR1XS
KS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ZTWM2OD13Lkm4PFM3KM7:TR?= NIDzU|RUSU6JRWK=
647-V Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTEdopkUUN3ME21Mlk6OTR6IN88US=> MlfWV2FPT0WU
COLO-679 NUOybFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XiTGlEPTB;Nj6wNFI2PSEQvF2= NWTCcVZoW0GQR1XS
AN3-CA M3THRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTZwMEO0OFEh|ryP M{DjR3NCVkeHUh?=
C32 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M131WmlEPTB;Nj6xN|A{PCEQvF2= M2LNTHNCVkeHUh?=
KM12 M{PXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D2OGlEPTB;Nj6yOFA6QSEQvF2= MWHTRW5ITVJ?
KINGS-1 M4\hfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmO|VKSzVyPU[uNlYyPTJizszN M1P6U3NCVkeHUh?=
KYSE-410 M{DTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSxTWM2OD14LkOwOlQ2KM7:TR?= NH;LbGNUSU6JRWK=
HPAF-II NYnTWVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;3OWlEPTB;Nj6zOVQ5KM7:TR?= MYfTRW5ITVJ?
LAN-6 NIXRR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjuTmNjUUN3ME22MlQ6PjNzIN88US=> NIjF[|NUSU6JRWK=
LU-99A MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xOGlKSzVyPU[uOVU6QDlizszN NFPoflRUSU6JRWK=
SJSA-1 NFqxeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;je4RkUUN3ME22MlU3OzR5IN88US=> M4PaPXNCVkeHUh?=
MSTO-211H M164WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjCOnBsUUN3ME22MlczOjN|IN88US=> MVHTRW5ITVJ?
SW900 NEPOOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXvTmtKSzVyPU[uO|YzOjFizszN MoX6V2FPT0WU
LNCaP-Clone-FGC MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRS5FKSzVyPU[uPFA1ODNizszN Mmn6V2FPT0WU
OMC-1 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;WfoxKSzVyPU[uPFU1ODJizszN M3\CSnNCVkeHUh?=
IST-MEL1 M4nXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZwOEm2Olkh|ryP M1LYRXNCVkeHUh?=
TE-9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwOEm4OFch|ryP MWrTRW5ITVJ?
NCI-H2030 NHq3dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi3VZdIUUN3ME22MlkyOjJ4IN88US=> NIP5THRUSU6JRWK=
BFTC-909 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\R[mlEPTB;Nz6wNFY1OSEQvF2= M1z4UnNCVkeHUh?=
NCI-SNU-5 NX3o[VZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\QeVR5UUN3ME23MlAzOTV7IN88US=> M{e2W3NCVkeHUh?=
TE-5 NH6xSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HLZ2lEPTB;Nz6wNlg5OSEQvF2= NVHKeXhKW0GQR1XS
SK-MES-1 NWfWS3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:2cGlEPTB;Nz6wOVQzPyEQvF2= MoTpV2FPT0WU
SHP-77 NF;ncG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrHWHVKSzVyPUeuNVM6PTJizszN NGTsemxUSU6JRWK=
NCI-H1623 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEflSJhKSzVyPUeuNVQxPzJizszN M4TwWnNCVkeHUh?=
TE-11 M2nFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD15LkG1NVg1KM7:TR?= MX\TRW5ITVJ?
EKVX M3vrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwMUmyOlch|ryP MYHTRW5ITVJ?
OVCAR-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjZNHFKSzVyPUeuNlEyOzNizszN MlnDV2FPT0WU
C3A NXL0ToI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTdwM{S1NkDPxE1? Ml7rV2FPT0WU
CFPAC-1 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfpTWM2OD15LkO2NlIzKM7:TR?= MV3TRW5ITVJ?
MG-63 NX\Je3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LRSGlEPTB;Nz60NVg1QSEQvF2= M1HnV3NCVkeHUh?=
KYSE-140 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K0T2lEPTB;Nz60OFA3OSEQvF2= MkjkV2FPT0WU
MPP-89 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKRY9FUUN3ME23MlU6PzJ7IN88US=> MnjLV2FPT0WU
COLO-824 M4i5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f2[mlEPTB;Nz63Nlg3OyEQvF2= NFK1V5pUSU6JRWK=
SiHa MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwOEO3NFch|ryP Mlu0V2FPT0WU
SNU-387 M3WxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTdwOEWzOFch|ryP M4eybHNCVkeHUh?=
A172 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTdwOE[xO|Ih|ryP MofxV2FPT0WU
COLO-680N M1z2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:1[WZUUUN3ME23MlkyPzNizszN MnHUV2FPT0WU
HCC1395 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPvXYdKSzVyPUiuNFU1PTJizszN M3TSZ3NCVkeHUh?=
NCI-H28 NHThc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH30SFhKSzVyPUiuNFU6PjNizszN M4XnNnNCVkeHUh?=
LC-2-ad NInmdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq5UmJKSzVyPUiuNlE6OzdizszN M3X6dHNCVkeHUh?=
S-117 M1[4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;aUXluUUN3ME24MlI2OzV|IN88US=> NW\YR3BuW0GQR1XS
NCI-H1838 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknMTWM2OD16LkK1O|gyKM7:TR?= Ml7DV2FPT0WU
PANC-10-05 NY[wT4Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6RZZ6UUN3ME24MlM4ODR5IN88US=> MYDTRW5ITVJ?
KALS-1 NUDFe5NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tmb2lEPTB;OD61NFkzQCEQvF2= MmHyV2FPT0WU
LS-1034 NV3l[mFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPMfJRKSzVyPUiuOVc1OzdizszN NFW1cVFUSU6JRWK=
TGBC1TKB NH3pZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW0TWM2OD16LkezOVM2KM7:TR?= MnnHV2FPT0WU
OE19 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7IRnpKSzVyPUiuO|YzPjJizszN NUT3UZpyW0GQR1XS
D-502MG M1H5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRThwN{[5PVQh|ryP NULhc45IW0GQR1XS
JEG-3 NYGzdnl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwN{i2NVgh|ryP MXTTRW5ITVJ?
DBTRG-05MG NEK3bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[2cJhKSzVyPUiuPFc2PjVizszN NHq0SJpUSU6JRWK=
ME-180 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjUXmlIUUN3ME25MlA3PzJ3IN88US=> NVK5eoZmW0GQR1XS
NCI-H1573 NYXDfoJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwMUC1N|Ih|ryP NV\xO|I2W0GQR1XS
HCC2998 NGi1SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD17LkGzOlgyKM7:TR?= NVrwUoo6W0GQR1XS
ACHN M1XyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmzTWM2OD17LkK0PVc2KM7:TR?= MXjTRW5ITVJ?
D-392MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLBTWM2OD17LkK1O|E2KM7:TR?= M1z6e3NCVkeHUh?=
no-11 NE\hU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTlwMk[wNlgh|ryP MULTRW5ITVJ?
KLE NXrRNXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2wTWM2OD17LkOyNlMzKM7:TR?= NG\1OmlUSU6JRWK=
Calu-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXWVGhmUUN3ME25MlM4PTJ6IN88US=> M3PNWXNCVkeHUh?=
LB831-BLC NYXnUotqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzhWYh7UUN3ME25MlQ2OTdzIN88US=> MkXHV2FPT0WU
SW684 NWLYbJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTlwNE[xNVYh|ryP NULsV5QxW0GQR1XS
SH-4 M4C0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLiTWM2OD17LkS5N|Y1KM7:TR?= M2n1RnNCVkeHUh?=
IST-MES1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3NTWM2OD17LkWxOlQ1KM7:TR?= M{\penNCVkeHUh?=
Saos-2 M{TvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XsdmlEPTB;OT61NlE6PSEQvF2= NVPsS|k6W0GQR1XS
NCI-H2087 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLjfY41UUN3ME25MlY4OzV{IN88US=> MYTTRW5ITVJ?
SCC-9 NEW0ZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLzeW1KSzVyPUmuO|E5OTZizszN M4C3R3NCVkeHUh?=
MFE-280 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqVYtCUUN3ME25MlczPzh3IN88US=> MkfNV2FPT0WU
BEN MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;0b2lEPTB;OT64NlE2QSEQvF2= MVvTRW5ITVJ?
CP50-MEL-B NWL6S5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fLTmlEPTB;OT65NlQ{OiEQvF2= M{[yOXNCVkeHUh?=
SK-MEL-28 NIW3VYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX2WlZKSzVyPUGwMlAyQTNizszN M1LNVXNCVkeHUh?=
NCI-H2452 M4D4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JNI1CUUN3ME2xNE4yPiEQvF2= MXnTRW5ITVJ?
NCI-H1395 NITiZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPTS3JnUUN3ME2xNE4yPzhizszN MkGwV2FPT0WU
NCI-H2052 NWfkRWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvyNFdTUUN3ME2xNE4yQDh{IN88US=> M2PXdXNCVkeHUh?=
A375 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFyLkK0OVIh|ryP MXjTRW5ITVJ?
HCC38 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPCVVNSUUN3ME2xNE4{OjJizszN NUDOWFZkW0GQR1XS
LK-2 M{jvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjWTWM2OD1zMD60NlA5KM7:TR?= NY\hTGdUW0GQR1XS
SF126 M3XPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn2PW9KSzVyPUGwMlQ4OjdizszN MWPTRW5ITVJ?
SK-MEL-1 NYTGbY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHSTWM2OD1zMD63PFM5KM7:TR?= MlfSV2FPT0WU
ACN MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\COmlEPTB;MUCuPFY4QSEQvF2= NHXGV|hUSU6JRWK=
BB30-HNC NHX4[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyLki3NVEh|ryP MVHTRW5ITVJ?
NCI-H747 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyLki3OFYh|ryP MnXqV2FPT0WU
KYSE-150 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLINZUzUUN3ME2xNU4xOzh5IN88US=> NUTmUnVRW0GQR1XS
D-247MG NX;rT4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDkTVhKSzVyPUGxMlExODlizszN MmTVV2FPT0WU
BxPC-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDsbWJsUUN3ME2xNU4{PzR5IN88US=> M1XXWHNCVkeHUh?=
SK-MEL-30 M33QfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPVTWM2OD1zMT60NFc6KM7:TR?= MlK3V2FPT0WU
CAS-1 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rmN2lEPTB;MUGuOFExQSEQvF2= MlrXV2FPT0WU
no-10 NYLyTlBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzEcllKSzVyPUGyMlEzOTdizszN MUDTRW5ITVJ?
NCI-H2405 M3\tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLETWM2OD1zMj6yNFM3KM7:TR?= MWrTRW5ITVJ?
KGN NHztTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2TWM2OD1zMj6yPVAyKM7:TR?= MVvTRW5ITVJ?
BB49-HNC M1:wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD1zMj6zPVU3KM7:TR?= MkHSV2FPT0WU
NCI-H1693 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LPc2lEPTB;MUKuOVgyPiEQvF2= MmfEV2FPT0WU
RO82-W-1 NF;5N3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPzTWM2OD1zMz6wOlQ6KM7:TR?= NYXNUZJoW0GQR1XS
CAL-85-1 NUHURpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF|LkSzPVkh|ryP MlXpV2FPT0WU
H-EMC-SS NWXDWIdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPkTWM2OD1zMz65NVA1KM7:TR?= MniwV2FPT0WU
SW1783 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF2LkKzPVEh|ryP NY\jWpN4W0GQR1XS
LB771-HNC MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF2LkSxPUDPxE1? MYDTRW5ITVJ?
HCC70 NF3WWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD1zND60NlM{KM7:TR?= M4\VOXNCVkeHUh?=
KNS-81-FD MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLOTWM2OD1zND63NFQ2KM7:TR?= Moq3V2FPT0WU
KYSE-520 M4S0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLHTWM2OD1zND65Nlch|ryP MXHTRW5ITVJ?
TGBC24TKB NHfDRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17MUmlEPTB;MUSuPVU{QSEQvF2= MYjTRW5ITVJ?
SNB75 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPqTWM2OD1zNT6wO|I6KM7:TR?= M1rvXnNCVkeHUh?=
SW872 NW\FXGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLOPVJHUUN3ME2xOU4zOjF6IN88US=> NYXycYpnW0GQR1XS
U031 M33aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ewSGlEPTB;MUWuPFAzQCEQvF2= MoTQV2FPT0WU
ChaGo-K-1 NIHpNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD3WFY1UUN3ME2xOU45OzV7IN88US=> MoHPV2FPT0WU
NCI-H441 NGf4dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG0RoRKSzVyPUG2MlAxOzlizszN MnPGV2FPT0WU
TE-12 NXrieY01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\sTWM2OD1zNj6xPFc{KM7:TR?= MkHOV2FPT0WU
NCI-H1755 NIS1WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXQTWM2OD1zNj61O|Mh|ryP MUnTRW5ITVJ?
KNS-42 NY\JemN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfYPYtKSzVyPUG2MlY2QDlizszN MkXKV2FPT0WU
SK-PN-DW NVTzNHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHOW3NtUUN3ME2xO{41OjBzIN88US=> M37RfHNCVkeHUh?=
NCI-H226 NVrDXVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV36XFdTUUN3ME2xO{46OzR3IN88US=> MXLTRW5ITVJ?
K-562 M33kO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIT4ZKSzVyPUG4MlY{OTdizszN MXXTRW5ITVJ?
A388 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DXdmlEPTB;MUmuNFMxOyEQvF2= M2DCZnNCVkeHUh?=
ZR-75-30 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnYS|BTUUN3ME2xPU4xQTZ6IN88US=> M2f0ZXNCVkeHUh?=
LU-135 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\2TWM2OD1zOT6yOlM3KM7:TR?= Ml;LV2FPT0WU
NCI-H2029 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF7Lk[wNlEh|ryP NGHt[HRUSU6JRWK=
HT-1197 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPGTWM2OD1zOT65NlI4KM7:TR?= MXrTRW5ITVJ?
IGR-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrucnhvUUN3ME2yNE4{OTF5IN88US=> NIS3O3RUSU6JRWK=
U-87-MG NHrhZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTC[nQ4UUN3ME2yNE43PDF|IN88US=> NFHReGxUSU6JRWK=
NCI-H1304 M33zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJyLke1NFEh|ryP Mnr3V2FPT0WU
RCC10RGB M2DVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHiZm1KSzVyPUKxMlI5OjlizszN M1vkenNCVkeHUh?=
NCI-H520 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3rdY5JUUN3ME2yNk44PjFzIN88US=> MlLjV2FPT0WU
SK-LU-1 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL5dGhKSzVyPUKzMlA4OThizszN M{\qNnNCVkeHUh?=
UACC-893 NWjhbWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNV2ZKSzVyPUKzMlExOzhizszN MUXTRW5ITVJ?
NCI-H2347 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ|LkK2O|Qh|ryP MUPTRW5ITVJ?
U-118-MG MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ|LkeyNVch|ryP MWnTRW5ITVJ?
NCI-H596 NIWzOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nneWlEPTB;MkOuPVA2PSEQvF2= MXvTRW5ITVJ?
MZ1-PC M3\HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nmRmlEPTB;MkSuOlc2QSEQvF2= MYrTRW5ITVJ?
SW1417 NV;3fWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PVTmlEPTB;MkWuNlQ6QCEQvF2= MlzxV2FPT0WU
NCI-H82 NYLyR4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\kWodbUUN3ME2yOk41Ojh6IN88US=> MV;TRW5ITVJ?
COLO-678 NFrUNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvFd4pKSzVyPUK3MlQ6OTlizszN NVvkZoloW0GQR1XS
KURAMOCHI NHLW[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNblRZUUN3ME2yPE4yOjZizszN M3nmO3NCVkeHUh?=
NCI-H1650 NX\WdZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXoeW5KSzVyPUOwMlE6OjRizszN MXHTRW5ITVJ?
HCC1954 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TjUGlEPTB;M{GuN|Y3PiEQvF2= Ml3xV2FPT0WU
GAK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1|Mj6yOlE3KM7:TR?= MUXTRW5ITVJ?
YAPC NX22O|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fFXmlEPTB;M{OuO|Y1QCEQvF2= NFLMSYZUSU6JRWK=
NCI-H2228 NEOwe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDS2lEPTB;M{SuN|YxPSEQvF2= NX3JdplqW0GQR1XS
VMRC-RCZ MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm3cYZ6UUN3ME2zOk4{ODJ{IN88US=> Ml;sV2FPT0WU
NMC-G1 NFTkc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvbnNKSzVyPUO3MlA2OjlizszN MXvTRW5ITVJ?
D-336MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRzLki0OFIh|ryP MULTRW5ITVJ?
UACC-62 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHlSJZKSzVyPUSyMlU2ODVizszN NHvFS2RUSU6JRWK=
C-33-A MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD12NT6zNlU3KM7:TR?= NVjOWnk3W0GQR1XS
HCC1937 M2jlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFizN|FKSzVyPUS3MlE6PThizszN MU\TRW5ITVJ?
HDLM-2 NXrWWWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDiemJtUUN3ME20O{4zOjh5IN88US=> NVTxZ|NZW0GQR1XS
NCI-H727 NELRNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGzNXFsUUN3ME20O{4zPDVzIN88US=> NGrMXnJUSU6JRWK=
NY M3T2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyO2lEPTB;NEmuN|kxQCEQvF2= NWTmfYdiW0GQR1XS
NCI-H2291 NE\kO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LKc2lEPTB;NEmuPFMxOSEQvF2= MofHV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

Protocol

Kinase Assay:

[1]
+ Expand

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research:

[2]
+ Expand
  • Cell lines: LNCaP, PC-3, and TSU-Pr1
  • Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
  • Incubation Time: 1, 2, 3 and 4 days
  • Method:

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • Formulation: Dissolved in DMSO
  • Dosages: ~100 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 264.3
Formula

C14H20N2O3
CAS No. 149647-78-9
Storage powder
in solvent
Synonyms SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center December 2018 Early Phase 1
NCT03263533 Recruiting Schizophrenia Virginia Commonwealth University December 1 2018 Early Phase 1
NCT03259503 Not yet recruiting Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Lymphoma M.D. Anderson Cancer Center|AstraZeneca November 2018 Phase 1|Phase 2
NCT03713320 Recruiting Cutaneous T-Cell Lymphoma/Mycosis Fungoides miRagen Therapeutics Inc. October 2018 Phase 2
NCT03382834 Active not recruiting HIV Infections National Institute of Allergy and Infectious Diseases (NIAID) April 26 2018 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • Answer:

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) supplier | purchase Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) manufacturer | order Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID